

## **NASHAT Y. GABRAIL, M.D.**

*Oncologist/Hematologist*

### **OFFICE**

4875 Higbee Ave NW - Canton, Ohio 44718

Phone (330) 492-3345

### **PERSONAL DATA**

Born March 21, 1952 - Neneveh, Iraq

### **QUALIFICATIONS**

- M.D. - Mosul College of Medicine, Mosul, Iraq, 1976
- M.R.C.P. - Member of the Royal College of Physicians, United Kingdom, 1982
- MRCPPath - Member of the Royal College of Pathologists, London, United Kingdom, 1984
- Member of the American Board of Internal Medicine, 1987
- Member of the American Board of Medicine (Oncology), 1989

### **EXPERIENCE**

- 2015 – Present    Clinical Research Trials, Canton, Ohio  
**President and Medical Director**
- 2014 – Present    Ohio University Heritage College of Osteopathic Medicine  
**Clinical Associate Professor of Oncology**
- 2014 - Present    Sargon Research, Canton, Ohio  
**President and Medical Director**
- 2013 - Present    EHCS Employer Health Care Savings  
**Co-Founder and Medical Director**
- 1990 - Present    Gabrail Cancer Center & Gabrail Cancer Center Research, Canton, Ohio  
**President**
- 1988 - 1990      St. Louis University Hospital, St. Louis, Missouri  
**Assistant Professor of Medicine, Division of Hematology/Oncology and BMT**
- 1987 - 1988      University of Missouri Hospital and Clinics, Columbia, Missouri  
**Fellow in Hematology/Oncology**
- 1985 - 1987      Hurley Medical Center, Flint, Michigan  
**Resident, Internal Medicine**
- 1983 - 1984      Southern General Hospital, Glasgow, Scotland  
**Registrar, Department of Hematology**
- 1981 - 1983      Western General Hospital, Edinburg, Scotland  
**Registrar, Department of Hematology**
- 1977 - 1980      University of Saladin Irbil, Iraq  
**Lecturer in Hematology and Pathology**
- 1976 - 1977      Medical City of Baghdad, Iraq  
**Internship**

Nashat Y Gabrail, M.D.

## **SPECIAL EXPERIENCE**

- 1990 - Present    Gabrail Cancer Center, Canton, Ohio  
Cooperative Group and Industry Sponsored Clinical Trials  
Specializing in Bioequivalence, Phase 0, and Phase 1 Oncology Studies
- 1989                Fred Hutchinson Cancer Center, Seattle, Washington  
Three months sabbatical in Bone Marrow Transplantation
- 1984                West of Scotland Transfusion Center, Carlouk, Scotland  
Two weeks of intensive training in Blood Banking and Blood Transfusion, Monitoring the safety  
of blood products

## **AWARDS/ACKNOWLEDGEMENTS**

- 2016                Author, The Cancer Gene
- 2009                Author; Good Medicine is Cheaper Medicine
- 2008                “Best Small Oncology Practice in Patient care”; Hematology Oncology News and Issues, (HOPE)
- 2008                “Best Facility Design”; Hematology Oncology News and Issues, (HOPE)
- 2008                “Best Small Oncology Practice in Revenue Strategy”; Hematology Oncology News and Issues,  
(HOPE)
- 2008                “Business of Excellence” Award, Greater Canton Chamber of Commerce
- 2008                “Clinical Best Practice Award”; Hematology Oncology News and Issues, (HOPE)
- 2008                ASCO Foundation Community Oncology Research Award Nominee by the Ohio West Virginia  
Oncology Society
- 2004                Recognized as one of the top 400 research centers in the world by PRA International

## **ORGANIZATION MEMBERSHIPS**

- 2010 - Present    Member of the Board of Advisors, International Oncology Network; ION Solutions, Frisco, TX
- 2014 - Present    Trustee of OHOS (Ohio Hematology Oncology Society)
- 2015 - Present    Board Member COA (Community Oncology Alliance)
- 2015 - Present    Member of CCTA (Coalition of Clinical Trial Awareness) , Board of Directors
- 2015 - Present    Member Heron Therapeutics STUSTOL Steering Committee
- 2012 - Present    Member of the Board of Directors, Aultman Cancer Center of Excellence, LLC, Canton, Ohio
- 2007 - Present    Past Member of the Editorial Board for Hematology & Oncology News and Issues (HONI)
- 2000 - 2006        Past President, Assyrian Medical Society
- 1984                Member of the Royal College of Physicians and Edinburgh, UK
- 1982                Member of the Royal College of Pathologists of London, UK

Nashat Y Gabrail, M.D.

2003 - Present Consultant for CRO's and Pharmaceutical Industry in the design and writing of Clinical Protocols

2006 - Present Columnist for regional newspapers (The Repository, The Times-Reporter, The Observer, and The Budget)

## PUBLICATIONS

- Ian D Schnadig<sup>1</sup>, Richey Agajanian<sup>2</sup>, Christopher Dakhil<sup>3</sup>, **Nashat Gabrail<sup>4</sup>**, Jeffrey Vacirca<sup>5</sup>, Charles Taylor<sup>6</sup>, Sharon Wilks<sup>7</sup>, Eduardo Braun<sup>8</sup>, Michael C Mosier<sup>9</sup>, Robert B Geller<sup>10</sup>, Lee Schwartzberg<sup>11</sup>, Nicholas Vogelzang<sup>12</sup> <sup>1</sup>Compass Oncology, US Oncology Research, Tualatin, OR, <sup>2</sup>The Oncology Institute of Hope and Innovation, Whittier, CA, <sup>3</sup>Cancer Center of Kansas, Wichita, KS, <sup>4</sup>**Gabrail Cancer Center, Canton, OH**, <sup>5</sup>North Shore Hematology Oncology, East Setauket, NY, <sup>6</sup>Tulsa Cancer Institute, Tulsa, OK, <sup>7</sup>Cancer Care Centers of South Texas, San Antonio, TX, <sup>8</sup>Michiana Hematology Oncology, Westville, IN, <sup>9</sup>Biostatistics, EMB Statistical Solutions, LLC, Overland Park, KS, <sup>10</sup>Medical Affairs, Heron Therapeutics, Inc., San Diego, CA, <sup>11</sup>West Cancer Center, Germantown, TN, <sup>12</sup>Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA: **APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial** *Cancer Management and Research*. Volume 9 19 May 2017
- Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni R.A. Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan J. Ramus, Fei Huang, Nolan Priedigkeit, Estefania Rodriguez, Michael Donovan, Faisal Khan, Tamara Kalir, Robert Sebra, Andrew Uzilov, Rong Chen, Rileen Sinha, Richard Halpert, Jean-Noel Billaud, Sharon Shacham, Dilara McCauley, Yosef Landesman, Tami Rashal, Michael Kauffman, Mansoor R. Mirza, Morten Mau-Sørensen, Peter Dottino and John A. Martignetti: **Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer**. *Clinical Cancer Research*. Volume 23 Issue 6 March 2017
- Ruben Niesvizky, MD<sup>1</sup>, Paul G. Richardson, MD<sup>2</sup>, Andrew J. Yee, MD<sup>3</sup>, Ajay K Nooka<sup>4</sup>, Marc S Raab<sup>5</sup>, Kenneth H. Shain, MD, PhD<sup>6</sup>, **Nashat Y. Gabrail, MD<sup>7</sup>**, Jeffrey Matous, MD<sup>8</sup>, Amit B. Agarwal<sup>9</sup>, James Hoffman, MD<sup>10</sup>, Sumit Madan, MD<sup>11</sup>, John M. Pagel, MD PhD<sup>12</sup>, Jesus San Miguel, MD PhD<sup>13</sup>, Philippe Moreau<sup>14</sup>, Maria-Victoria Mateos, MD, PhD<sup>15</sup>, Thierry Facon<sup>16</sup>, David Tamang, PhD<sup>17</sup>, Simon S Jones, PhD<sup>18</sup>, Robert J Markelewicz Jr., MD<sup>17</sup>, Catherine Wheeler, MD<sup>17</sup>, Nikolaus S. Trede, MD, PhD<sup>17</sup>, Noopur Raje, MD<sup>19</sup>, Evangelos Terpos<sup>20</sup> and William I. Bensinger, MD<sup>21</sup> <sup>1</sup>Weill Cornell Medical College, New York, NY, <sup>2</sup>Dana-Farber Cancer Institute, Boston, MA, <sup>3</sup>Massachusetts General Hospital Cancer Center, Boston, MA, <sup>4</sup>Division of BMT, Winship Cancer Institute - Hematology and Medical Oncology, Emory University, Atlanta, GA, <sup>5</sup>Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany, <sup>6</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, <sup>7</sup>**Gabrail Cancer Center, Canton, OH**, <sup>8</sup>Colorado Blood Cancer Institute, Denver, CO, <sup>9</sup>University of Arizona Cancer Center, Tucson, AZ, <sup>10</sup>Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, <sup>11</sup>Hematology-Oncology, Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, TX, <sup>12</sup>Swedish Medical Center, Seattle, WA, <sup>13</sup>CIMA/UNAV/IDISNA, Pamplona, Spain, <sup>14</sup>Department of Hematology, Nantes University Hospital, Nantes, France, <sup>15</sup>Hematology, University Hospital of Salamanca-IBSAL, Salamanca, Spain, <sup>16</sup>Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France, <sup>17</sup>Acetylon Pharmaceuticals, Inc., Boston, <sup>18</sup>Acetylon Pharmaceuticals, Inc., Boston, MA, <sup>19</sup>Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, <sup>20</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>21</sup>Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA: **Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)**. ASH 2016. Poster Presentation. December 2016
- Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kabbinavar F: **A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin,**

**paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.** *OncoTargets and Therapy*. Volume 9. 30 November 2016

- **Nashat Gabrail,<sup>1</sup> Ronald Yanagihara,<sup>2</sup> Marek Spaczyński,<sup>3</sup> William Cooper,<sup>4</sup> Erin O'Boyle,<sup>5</sup> Carrie Smith,<sup>1</sup> and Ralph Boccia<sup>6</sup>** **Gabrail Cancer Center, Canton, OH, USA,** <sup>2</sup>St Louise Regional Hospital, Gilroy, CA, USA, <sup>3</sup>Department of Gynecology, Obstetrics and Gynecologic Oncology, University of Medical Sciences, Poznan, Poland, <sup>4</sup>TFS International, Flemington, NJ, USA, <sup>5</sup>FibroGen, Inc., San Francisco, CA, USA, <sup>6</sup>Center for Cancer and Blood Disorders, Bethesda, MD, USA: **Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.** *Cancer Manag Res*. Volume 7. March 2015
- John Kuruvilla, MD<sup>1</sup>, John C. Byrd, MD<sup>2</sup>, Joseph M Flynn<sup>3</sup>, Ramiro Garzon, MD<sup>3</sup>, Pierluigi Porcu, MD<sup>4</sup>, Nina Wagner-Johnston<sup>5</sup>, Mary Lynn Savoie, MD, FRCPC<sup>6</sup>, Richard M. Stone, MD<sup>7</sup>, Eric D. Jacobsen, MD<sup>7</sup>, Morten Mau-Sorensen, MD<sup>8</sup>, Peter de Nully Brown<sup>9</sup>, Rachid Baz, MD<sup>10</sup>, Bijal Shal, MD<sup>11</sup>, Ian Flinn<sup>12</sup>, **Nashat Gabrail, MD<sup>13</sup>**, Vishal Kukreti, MD<sup>14</sup>, Rodger E. Tiedemann, MD, PhD<sup>14</sup>, Yosef Landesman, PhD<sup>15</sup>, Boris Klebanov, M.A., MSc<sup>15</sup>, Eran Shacham, PhD<sup>15</sup>, Jean-Richard Saint-Martin<sup>16</sup>, Tracey Marshall<sup>16</sup>, John McCartney, PhD<sup>17</sup>, Dilara McCauley, PhD<sup>15</sup>, Robert Carlson, PhD<sup>15</sup>, Sasha Norori, MSc<sup>18</sup>, Michael R Savona, MD<sup>16</sup>, Tami Rashal, MD<sup>15</sup>, Mansoor R Mirza, MD<sup>16</sup>, Michael Kauffman, MD, PhD<sup>15</sup> and Sharon Shacham, PhD, MBA<sup>15</sup> **Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada** <sup>2</sup>The Ohio State University Medical Center, Columbus, OH <sup>3</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH <sup>4</sup>Division of Hematology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH <sup>5</sup>Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO <sup>6</sup>Alberta Health Services, Calgary, AB, Canada <sup>7</sup>Dana-Farber Cancer Institute, Boston, MA <sup>8</sup>Department of Oncology Rigshospitalet, Copenhagen, Denmark <sup>9</sup>Department of Oncology, Rigshospitalet, Copenhagen, Denmark <sup>10</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL <sup>11</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL <sup>12</sup>Sarah Cannon Research Institute, Nashville, TN <sup>13</sup>**Gabrail Cancer Center, Canton, OH** <sup>14</sup>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada <sup>15</sup>Karyopharm Therapeutics, Inc, Newton, MA <sup>16</sup>Karyopharm Therapeutics, Newton, MA <sup>17</sup>Karyopharm Therapeutics Inc, Newton, MA <sup>18</sup>Ozmosis Research Inc., Toronto, ON, Canada: **The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL).** ASH 2014. Oral Presentation. December 2014
- Parameswaran N. Hari, MD<sup>1</sup>, Kenneth H. Shain, MD, PhD<sup>2</sup>, Peter M. Voorhees, MD<sup>3</sup>, **Nashat Gabrail, MD<sup>4</sup>**, Muneer H. Abidi, MD<sup>5</sup>, Jeffrey Zonder, MD<sup>5</sup>, Ralph V. Boccia, MD<sup>6</sup>, Paul G. Richardson<sup>7</sup>, Linda L. Neuman, MD, MBA<sup>8</sup>, Sandra J. Dixon, MS<sup>9</sup> and Claudia Paba Prada, MD<sup>10</sup> <sup>1</sup>Department of Medicine, Medical College of Wisconsin, Milwaukee, WI <sup>2</sup>H. Lee Moffitt Cancer Center, Tampa, FL <sup>3</sup>Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC <sup>4</sup>Gabrail Cancer Center, Canton, OH <sup>5</sup>Wayne State University, Karmanos Cancer Center, Detroit, MI <sup>6</sup>Center for Cancer and Blood Disorders, Bethesda, MD <sup>7</sup>The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA <sup>8</sup>Onyx Pharmaceuticals, Inc., Redwood City, CA <sup>9</sup>Onyx Pharmaceuticals, Inc., South San Francisco, CA <sup>10</sup>Dana-Farber Cancer Institute, Boston, MA: **Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study.** ASH 2014. Oral and Poster Abstract. December 2014
- Christine I. Chen, MD, MEd, FRCPC<sup>1</sup>, Martin Gutierrez, MD<sup>2</sup>, David S. Siegel, MD, PhD<sup>2</sup>, Joshua R. Richter, MD<sup>3</sup>, Nina Wagner-Johnston<sup>4</sup>, Craig C Hofmeister, MD, MPH<sup>5</sup>, Jesus G. Berdeja, MD<sup>6</sup>, **Nashat Gabrail, MD<sup>7</sup>**, Rachid Baz, MD<sup>8</sup>, Morten Mau-Sorensen, MD<sup>9</sup>, Suzanne Trudel, MD, MSc, FRCPC<sup>10</sup>, Rodger E. Tiedemann, MD, PhD<sup>1</sup>, Vishal Kukreti, MD<sup>1</sup>, Nuchanan Areethamsirikul, MD<sup>11</sup>, Asfar Azmi, PhD<sup>12</sup>, Trinayan Kashyap, MSc<sup>13</sup>, Yosef Landesman, PhD<sup>13</sup>, Tracey Marshall<sup>14</sup>, John McCartney, PhD<sup>15</sup>, Jean-Richard Saint-Martin<sup>14</sup>, Sasha Norori, MSc<sup>16</sup>, Michael R Savona, MD<sup>14</sup>, Tami Rashal, MD<sup>13</sup>, Robert Carlson, PhD<sup>13</sup>, Mansoor R Mirza, MD<sup>14</sup>, Sharon Shacham, PhD, MBA<sup>13</sup>, Michael Kauffman, MD, PhD<sup>13</sup> and Donna E Reece, MD, FRCPC<sup>1</sup> <sup>1</sup>Department of Medical Oncology and Hematology, Princess Margaret

Cancer Centre, Toronto, ON, Canada <sup>2</sup>John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ <sup>3</sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ <sup>4</sup>Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO <sup>5</sup>Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH <sup>6</sup>Sarah Cannon Research Institute, Nashville, TN <sup>7</sup>**Gabraïl Cancer Center, Canton, OH** <sup>8</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL <sup>9</sup>Rigshospitalet, Copenhagen, Denmark <sup>10</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada <sup>11</sup>Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada <sup>12</sup>Pathology, Wayne State University / Karmanos Cancer Institute, Detroit, MI <sup>13</sup>Karyopharm Therapeutics, Inc, Newton, MA <sup>14</sup>Karyopharm Therapeutics, Newton, MA <sup>15</sup>Karyopharm Therapeutics Inc, Newton, MA <sup>16</sup>Ozmosis Research Inc., Toronto, ON, Canada: **Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)**. ASH 2014. Oral and Poster Abstract. December 2014

- Harry Raftopoulos<sup>1</sup>, William Cooper<sup>2</sup>, Erin O'Boyle<sup>3</sup>, **Nashat Gabrail<sup>4</sup>**, Ralph Boccia<sup>5</sup>, Richard J Gralla<sup>6</sup>; (1)Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Road, Lake Success, NY, 11042, USA, (2)TFS International, 70 Church St, Flemington, NJ 08822, USA, (3)FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA, **(4)Gabraïl Cancer Center, 4875 Higbee Avenue NW, Canton, OH 44718, USA**, (5)Center for Cancer and Blood Disorders, 6410 Rockledge Drive #660, Bethesda, MD 20819, USA, (6)Albert Einstein College of Medicine, Jacobi Medical Center, 1400 Pelham Parkway South, Bronx, NY 10461, USA. **Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial**. *Support Care Cancer*. 2014 Sep 2. Epub 2014 Sep 2
- J. Martignetti<sup>1</sup>, A.R.A. Razak<sup>2</sup>, Y. Chen<sup>3</sup>, **N.Y. Gabrail<sup>4</sup>**, J.F. Gericitano<sup>5</sup>, C. Camacho<sup>3</sup>, E. Pereira<sup>3</sup>, B. Evans<sup>1</sup>, P. Dottino<sup>1</sup>, D. McCauley<sup>6</sup>, S. Shacham<sup>6</sup>, T. Rashal<sup>6</sup>, J. Saint-Martin<sup>6</sup>, E. Shacham<sup>6</sup>, D. Vincent<sup>7</sup>, M. Kauffman<sup>6</sup>, M.R. Mirza<sup>6</sup>, M. Mau-Sorensen<sup>8</sup> (1) Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY (2) Drug Development Program, Princess Margaret Cancer Center, Toronto, Canada; **(3) Gabraïl Cancer Center, Canton, OH, USA**; (4) Memorial Sloan Kettering Cancer Center, New York, NY, USA; (5) Karyopharm Therapeutics Inc, Newton, MA, USA; (6) Ozmosis Research Inc, Toronto, Canada; (7) Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark: **Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE™) Exportin 1 (XPO1) Antagonist Selinexor (KPT-330) in Patients (pts) with Platinum Resistant/Refractory Ovarian Cancer (OvCa)**. ESMO 2014, Abstract 7042, *Annals of Oncology* (2014) 25 (suppl\_4): iv305-iv326. 10.1093/annonc/mdu338, Poster, September 2014
- H. Mahaseth<sup>1</sup>, S.N. Maity<sup>2</sup>, **N.Y. Gabrail<sup>3</sup>**, A. Mahipal<sup>4</sup>, J.F. Gericitano<sup>5</sup>, S. Shacham<sup>6</sup>, T. Rashal<sup>7</sup>, B. Klebanov<sup>7</sup>, R. Carlson<sup>6</sup>, E. Shacham<sup>7</sup>, D. Vincent<sup>8</sup>, M. Kauffman<sup>7</sup>, A.F. Shields<sup>9</sup>, M.R. Mirza<sup>6</sup>, J.C. Araujo<sup>10</sup> (1) Karmanos Cancer Center, Wayne State University, 48201 - Detroit/US (2) Memorial Sloan Kettering Cancer Center, New York/US **(3) Gabraïl Cancer Center, Canton/US** (4)Medical Oncology (4) Moffitt Cancer Center, 33612 - Tampa/US (5) Memorial Sloan Kettering Cancer, New York/US (6) Karyopharm Therapeutics, Inc., 01760 - Natick/US (7) Karyopharm Therapeutics, 01760 - Natick/US (8) Ozmosis Research, Toronto/CA (9)Oncology, Karmanos Cancer Center, Wayne State University, 48201 - Detroit/US (10) MD Anderson Cancer Center, Houston/US: **Selinexor (KPT-330), an oral, selective inhibitor of nuclear export (SINE) shows anti-prostate cancer (PrCa) activity preclinically & disease control**. ESMO 2014, *Annals of Oncology* (2014) 25 (suppl\_4): iv255-iv279. 10.1093/annonc/mdu336, Poster, September 2014
- A. Mahipal<sup>1</sup>, **N.Y. Gabrail<sup>2</sup>**, A. Sukari<sup>3</sup>, H. Mahaseth<sup>3</sup>, M. Mau-Sorensen<sup>4</sup>, S. Shacham<sup>5</sup>, J. Saint-Martin<sup>6</sup>, S. Friedlander<sup>5</sup>, Y. Landesman<sup>6</sup>, J. Ellis<sup>6</sup>, E. Shacham<sup>6</sup>, J. McCartney<sup>6</sup>, T. Marshall<sup>6</sup>, D. Vincent<sup>7</sup>, T. Rashal<sup>6</sup>, M. Kauffman<sup>6</sup>, M.R. Mirza<sup>6</sup>, A.R.A. Razak<sup>8</sup> (1) Moffitt Cancer Center, Tampa, FL, USA; **(2) Gabraïl Cancer Center, Canton, OH, USA**; (3) Karmanos Cancer Institute, Detroit, MI, USA; (4) Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark; (5) Karyopharm Therapeutics Inc, Newton, MA, USA; (6) Ozmosis Research Inc., Toronto, Canada (7) Drug Development Program, Princess Margaret Cancer Center, Toronto, Canada: **Clinical activity of the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients with head & neck squamous cell carcinoma**. ESMO 2014,

*Annals of Oncology* (2014) 25 (suppl\_4): iv340-iv356. 10.1093/annonc/mdu340, Poster, September 2014

- Dariusz Wydra<sup>1</sup>, Sharad Anat Ghamande<sup>2</sup>, **Nashat Gabrail**<sup>3</sup>, Elzbieta Nowara<sup>4</sup>, Mariusz Bidzinski<sup>5</sup>, Stephen DePasquale<sup>6</sup>, Romnee Clark<sup>7</sup>, Richard T. Penson<sup>8</sup>; (1)Dept of Gynecology, Gynecological Oncology, and Gynecological Endocrinology, Medical University of Gdansk, Gdansk, Poland; (2)Georgia Regents University, Augusta, GA, USA; (3)**Gabrail Cancer Center, Canton, OH, USA**; (4)Cancer Center and Institute Gliwice Branch, Gliwice, Poland; (5)Specialist Hospital 'Inflancka', Department of Gynecological Oncology, Warsaw, Poland; (6)Chattanooga's Program in Women's Oncology, Chattanooga, TN, USA; (7)Endocyte, Inc, West Lafayette, IN, USA; (8)Massachusetts General Hospital, Boston, MA, USA: **PRECEDENT Subset Analysis: Safety and Disease Control with Vintafolide Monotherapy Following Discontinuation of Pegylated Liposomal Doxorubicin (PLD)**. ESMO 2014, *Annals of Oncology* (2014) 25 (suppl\_4): iv305-iv326. 10.1093/annonc/mdu338, Poster, September 2014
- Dariusz Wydra<sup>1</sup>, Sharad Anat Ghamande<sup>2</sup>, **Nashat Gabrail**<sup>3</sup>, Elzbieta Nowara<sup>4</sup>, Mariusz Bidzinski<sup>5</sup>, Stephen DePasquale<sup>6</sup>, Romnee Clark<sup>7</sup>, Richard T. Penson<sup>8</sup> (1)Dept of Gynecology, Gynecological Oncology, and Gynecological Endocrinology, Medical University of Gdansk, Gdansk, Poland; (2)Georgia Health Sciences University, Augusta, GA, USA; (3)**Gabrail Cancer Center, Canton, OH, USA**; (4)Cancer Center and Institute Gliwice Branch, Gliwice, Poland; (5)Specialist Hospital 'Inflancka', Department of Gynecological Oncology, Warsaw, Poland; (6)Chattanooga's Program in Women's Oncology, Chattanooga, TN, USA; (7)Endocyte, Inc, West Lafayette, IN, USA; (8)Massachusetts General Hospital, Boston, MA, USA: **Vintafolide and its Companion Imaging Agent, Etarfolatide – Results From a PRECEDENT Subanalysis**. EANM abstract, Poster, August 2014
- Nancy U. Lin, **Nashat Y. Gabrail**, John Sarantopoulos, Lee Steven Schwartzberg, Santosh Kesari, Susan Elaine Bates, Carey K. Anders, Anthony D. Elias, Jean-Paul Castaigne, Vihra Iordanova, Betty Lawrence, Razelle Kurzrock; Dana-Farber Cancer Institute, Boston, MA; **Gabrail Cancer Center, Canton, OH**; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio, San Antonio, TX; The University of Tennessee Health Science Center, Memphis, TN; University of California, San Diego, La Jolla, CA; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of Colorado Cancer Center, Aurora, CO; Angiochem, Inc., Montreal, QC, Canada; Angiochem Inc., Montreal, QC, Canada: **Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors**. 2014 ASCO Annual Meeting, Abstract 2523, *J Clin Oncol* 32:5s, 2014 (suppl; abstr 2523), Poster, 2014
- John Martignetti, Albiruni R.A. Razak, Ying Chen, **Nashat Y. Gabrail**, John F. Gerecitano, Catalina Camacho, Elena Pereira, Peter Remsen Dottino, Sharon Shacham, Dilara McCauley, Tami Rashal, Jean-Richard Saint-Martin, Eran Shacham, Darcy Vincett, Michael Kauffman, Mansoor Raza Mirza, Morten Sorensen; Mount Sinai School of Medicine, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; **Gabrail Cancer Center, Canton, OH**; Memorial Sloan-Kettering Cancer Center, New York, NY; Mt Sinai Medical Center, New York, NY; Karyopharm Therapeutics, Newton, MA; Ozmosis Research, Toronto, ON, Canada; Rigshospitalet, Copenhagen, Denmark: **Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa)**. 2014 ASCO Annual Meeting, Abstract 5522, *J Clin Oncol* 32:5s, 2014 (suppl; abstr 5522), Poster, 2014
- Karen W. L. Yee, Michael Savona, Morten Sorensen, Peter Brown, William G. Blum, Daniel J. DeAngelo, Martin Gutierrez, Ramiro Garzon, Andre C. Schuh, **Nashat Y. Gabrail**, Martha Wadleigh, Jeffrey E. Lancet, Bijal D. Shah, Jesus G. Berdeja, Nina D. Wagner-Johnston, Ian Flinn, Tami Rashal, Michael Kauffman, Sharon Shacham, Richard M. Stone; Princess Margaret Cancer Center, Toronto, ON, Canada; Tennessee Oncology, Nashville, TN; Rigshospitalet, Copenhagen, Denmark; H:S Rigshospitalet, The Finsen Centre, KAT, Haematology Department 4241, Copenhagen, Denmark; The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; John Theurer Cancer Center, Hackensack, NJ; **Gabrail Cancer Center, Canton, OH**; Dana-Farber Cancer Institute, Harvard University, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Sarah Cannon Research Institute, Nashville, TN; Washington University School of Medicine in St. Louis, St. Louis, MO; Karyopharm Therapeutics, Newton, MA: **A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML)**. 2014 ASCO Annual Meeting,

Abstract 7032, *J Clin Oncol* 32:5s, 2014 (suppl; abstr 7032), Poster, 2014

- Gilles A. Salles, Nicole Lamanna, Bipinkumar R. Amin, Ralph V. Boccia, **Nashat Y. Gabrail**, Muhammad-Ali A. Zaydan, Michelle Wong, Adeboye H. Adewoye, Paolo Ghia; Lyon Sud University Hospital, Pierre-Bénite, France; Memorial Sloan Kettering Cancer Center, New York, NY; Mid Dakota Clinic, Bismarck, ND; Center for Cancer and Blood Disorders, Bethesda, MD; **Gabraail Cancer Center, Canton, OH**; Montgomery Cancer Center, Mt. Sterling, KY; Gilead Sciences, Foster City, CA; Università Vita e Salute; San Raffaele Scientific Institute, Milano, Italy: **A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.** 2014 ASCO Annual Meeting, Abstract TPS7123, *J Clin Oncol* 32:5s, 2014 (suppl; abstr TPS7123), Poster, 2014
- Tomasz M. Beer, Sebastien J. Hotte, Johann Sebastian De Bono, Philippe Beuzebec, **Nashat Y. Gabrail**, Daniel Cain, Cindy Jacobs, Karim Fizazi; Oregon Health & Science University-Knight Cancer Institute, Portland, OR; Juravinski Cancer Centre, Hamilton, ON, Canada; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Medical Oncology Department, Institut Curie, Paris, France; **Gabraail Cancer Center, Canton, OH**; OncoGenex Pharmaceuticals, Inc., Bothell, WA; Institut Gustave Roussy, University of Paris, Villejuif, France: **Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.** 2014 Genitourinary Cancer Symposium, Abstract 222; *J Clin Oncol* 32, 2014 (suppl 4; abstr 222), Poster, 2014
- Eric Laille<sup>1</sup>, Sanjay Goel<sup>2</sup>, Alain C. Mita<sup>3</sup>, **Nashat Y. Gabrail**<sup>4</sup>, Kevin Kelly<sup>3</sup>, Liangang Liu<sup>1</sup>, Stephen Songer<sup>1</sup> and Charles L. Beach<sup>1</sup>; (1) Celgene Corporation, Summit, New Jersey; (2) Montelioro Einstein Cancer Center, Bronx, New York; (3) CTRC at the University of Texas Health Science Center, San Antonio, Texas; **(4) Gabrail Cancer Center, Canton, Ohio: A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment.** *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* Volume 34: Issue 5 pgs 440-451. May 2014
- Carrie Smith, RN, and **Nashat Gabrail, MD**, both in **Gabraail Cancer Center, Canton, OH: Phase 3 Study Comparing the efficacy and safety of sustained- release Granisetron (APF530) and Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving moderately or highly emeto-genic chemotherapy.** ONS 2014 Abstract #34. *Oncology Nursing Forum* Volume 41 Number 2 March 2014
- Naumann RW<sup>1</sup>, Coleman RL<sup>2</sup>, Burger RA<sup>4</sup>, Sausville EA<sup>5</sup>, Kutarska E<sup>6</sup>, Ghamande SA<sup>8</sup>, **Gabraail NY**<sup>9</sup>, Depasquale SE<sup>10</sup>, Nowara E<sup>7</sup>, Gilbert L<sup>11</sup>, Gersh RH<sup>12</sup>, Teneriello<sup>3</sup> MG, Harb WA<sup>13</sup>, Konstantinopoulos PA<sup>15</sup>, Penson RT<sup>16</sup>, Symanowski JT<sup>1</sup>, Lovejoy CD<sup>14</sup>, Leamon CP<sup>14</sup>, Morgenstern DE<sup>14</sup>, Messmann RA<sup>14</sup>.; (1)Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; (2) Anderson Cancer Center, University of Texas, Houston; (3)Texas Oncology, Austin, TX;(4) Fox Chase Cancer Center, Philadelphia, PA; (5) Greenebaum Cancer Center, University of Maryland, Baltimore, MD;(6) Centrum Onkologii Ziemi Lubelskiej, Lubland; (7) Instytut im. Marii Skłodowskiej-Curie, Gliwice, Poland;(8) Georgia Health Sciences University, Augusta, GA;**(9) Gabrail Cancer Center, Canton, OH**;(10) Chattanooga's Program in Women's Oncology, Chattanooga, TN;(11) McGill University Health Centre, Montreal, Quebec, Canada; (12) Cancer Care Northwest, Spokane, WA; (13), Horizon Oncology Research, Lafayette; (14), Endocyte, West Lafayette, IN; (15) Beth Israel Deaconess Medical Center; and (16) Dana-Farber Cancer Center, Massachusetts General Hospital, Boston, MA: **PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.** *J Clin Oncol.* 10;31(35):4400-6. Dec 2013
- Christine I. Chen, MD<sup>1</sup>, Martin Gutierrez, MD<sup>2</sup>, Peter de Nully Brown<sup>3</sup>, **Nashat Gabrail, MD**<sup>4</sup>, Rachid Baz, MD<sup>5</sup>, Donna E. Reece, MD<sup>6</sup>, Michael Savona, MD<sup>7</sup>, Suzanne Trudel, MD, MSC, FRCPC<sup>8</sup>, David S. Siegel, MD, PhD<sup>9</sup>, Morten Mau-Sorensen, MD<sup>10</sup>, John Kuruvilla, MD, FRCPC<sup>11</sup>, John C. Byrd, MD<sup>12</sup>, Sharon Shacham, PhD, MBA<sup>13</sup>, Tami Rashal, MD<sup>13</sup>, Cindy YF Yau, MSc, CCRP<sup>14</sup>, Dilara McCauley, PhD<sup>15</sup>, Jean-Richard Saint-Martin<sup>13</sup>, John McCartney, PhD<sup>13</sup>, Yosef Landesman, PhD<sup>13</sup>, Boris Klebanov<sup>13</sup>, Greg Pond, PhD<sup>14</sup>, Amit M. Oza, MBBS, MD<sup>14</sup>, Michael Kauffman, MD, PhD<sup>13</sup> and Mansoor R Mirza, MD<sup>16</sup>, <sup>1</sup>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>2</sup>Hackensack University Medical Centre, Hackensack, NJ, <sup>3</sup>Department of Hematology,

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, <sup>4</sup>**Gabrail Cancer Center, Canton, OH**, <sup>5</sup>Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, <sup>6</sup>Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>7</sup>Sarah Cannon Research Institute, Nashville, TN, <sup>8</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, <sup>9</sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, <sup>10</sup>Department of Oncology Rigshospitalet, Copenhagen, Denmark, <sup>11</sup>Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, <sup>12</sup>The Ohio State University, Columbus, OH, <sup>13</sup>Karyopharm Therapeutics Inc, Natick, MA, <sup>14</sup>Ozmosis Research Inc, Toronto, ON, Canada, <sup>15</sup>Karyopharm Therapeutics, Boston, MA, <sup>16</sup>Rigshospitalet, Copenhagen, Denmark: **Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM)**. ASH 2013, Abstract 1942; Poster , December 7, 2013

- Christopher J. Walker<sup>1</sup>, Joshua J. Oaks<sup>1</sup>, Ramasamy Santhanam<sup>1,2</sup>, Paolo Neviani<sup>1,3</sup>, Jason G. Harb<sup>1</sup>, Gregory Ferencak<sup>1</sup>, Justin J. Ellis<sup>1</sup>, Yosef Landesman<sup>4</sup>, Ann-Kathrin Einfeld<sup>1</sup>, **Nash Y. Gabrail**<sup>5</sup>, Carrie L. Smith<sup>5</sup>, Michael A. Caligiuri<sup>2,3</sup>, Peter Hokland<sup>6</sup>, Denis Claude Roy<sup>7</sup>, Alistair Reid<sup>8</sup>, Dragana Milojkovic<sup>8</sup>, John M. Goldman<sup>8</sup>, Jane Apperley<sup>8</sup>, Ramiro Garzon<sup>2,3</sup>, Guido Marcucci<sup>2,3</sup>, Sharon Shacham<sup>4</sup>, Michael G. Kauffman<sup>4</sup>, and Danilo Perrotti<sup>1,3,8</sup> <sup>1</sup>Human Cancer Genetics Program, Department Molecular Virology Immunology and Medical Genetics, <sup>2</sup>Department of Internal Medicine, and <sup>3</sup>Comprehensive Cancer Center, The Ohio State University, Columbus, OH; <sup>4</sup>Karyopharm Therapeutics Incorporated, Natick MA; <sup>5</sup>**Gabrail Cancer Center, Canton, OH**; <sup>6</sup>Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; <sup>7</sup>Department of Hematology-Oncology, Maisonneuve-Rosemont Hospital and University of Montreal, Montreal, QC, Canada; and <sup>8</sup>Department of Hematology, Hammersmith Hospital, Imperial College London, London, United Kingdom: **Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph<sup>+</sup> leukemias**. *Blood*. Volume 122: Number 17. October 24, 2013
- Richard Harrop, Franklin Chu, **Nashat Gabrail**, Sandy Srinivas, Daniel Blount & Anna Ferrari: **Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial**. *Cancer Immunology, Immunotherapy*. Volume 62: Number 8. August 2013
- Guillermo Garcia-Manero<sup>1</sup>, Elias Jabbour<sup>1</sup>, Gautam Borthakur<sup>1</sup>, Stefan Faderl<sup>1</sup>, Zeev Estrov<sup>1</sup>, Hui Yang<sup>1</sup>, Sirisha Maddipoti<sup>1</sup>, Lucy A. Godley<sup>2</sup>, **Nashat Gabrail**<sup>3</sup>, Jesus G. Berdeja<sup>4</sup>, Ahmed Nadeem<sup>5</sup>, Laurent Kassarow<sup>6</sup> and Hagop Kantarjian<sup>1</sup>; (1)The University of Texas MD Anderson Cancer Center, Houston, TX; (2)The University of Chicago, Chicago, IL; (3)**Gabrail Cancer Center, Canton, OH**; (4)Sarah Cannon Research Institute, Nashville, TN; (5)Landmark Medical Center, Woonsocket, RI; and (6) Eisai Pharmaceuticals, Woodcliff Lake, NJ: **Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes**. *Journal of Clinical Oncology* Volume 31: Number 20. July 10 2013
- Donald R. Taylor, Allen W. Burton, **Nashat Y. Gabrail**, Didier Mayeur, Philippe Poulain, Alain Serrie, Luis M. Torres: **Letter to the Editor: Pharmacokinetics of Non-Intravenous Formulations of Fentanyl**. *Clinical Pharmacokinetics* , Volume 52: Issue 5, pp 397-398. Apr 2013
- Feng Liu<sup>1</sup>, Moshe Talpaz<sup>2</sup>, Animesh Pardanani<sup>3</sup>, Catriona Jamieson<sup>4</sup>, **Nashat Gabrail**<sup>5</sup>, Ayalew Tefferi<sup>3</sup>, Tianlei Lei<sup>1</sup>, Rita Greco<sup>1</sup>, Francisco Adrian<sup>1</sup>, Nikki Daskalakis<sup>1</sup>, Claudia Lebedinsky<sup>1</sup>, Pamela Cohen<sup>1</sup>, and Donald Bergstrom<sup>1</sup>. <sup>1</sup>Sanofi Oncology, Cambridge, MA; <sup>2</sup>University of Michigan, Ann Arbor, MI; <sup>3</sup>Mayo Clinic, Rochester, MN; <sup>4</sup>Moore's UCSD Cancer Center, La Jolla, CA; <sup>5</sup>**Gabrail Cancer Center, Canton, OH**: **Abstract LB-294: Determination of JAK2V617F allele burden in a phase II study of patients with myelofibrosis treated with SAR302503 using a sensitive and robust allele-specific qPCR assay**. *Cancer Research*. Volume 73: Issue 8, Supplement 1. April 15, 2013
- Feng Liu<sup>1</sup>, Moshe Talpaz<sup>2</sup>, Animesh Pardanani<sup>3</sup>, Catriona Jamieson<sup>4</sup>, **Nashat Gabrail**<sup>5</sup>, Ayalew Tefferi<sup>3</sup>, Tianlei Lei<sup>1</sup>, Rita Greco<sup>1</sup>, Francisco Adrian<sup>1</sup>, Nikki Daskalakis<sup>1</sup>, Claudia Lebedinsky<sup>1</sup>, Pamela Cohen<sup>1</sup>, Donald Bergstrom<sup>1</sup>. <sup>1</sup>Sanofi Oncology, Cambridge, MA; <sup>2</sup>University of Michigan, Ann Arbor, MI; <sup>3</sup>Mayo Clinic, Rochester, MN; <sup>4</sup>Moore's UCSD Cancer Center, La Jolla, CA; <sup>5</sup>**Gabrail Cancer Center, Canton,**



**OH : LB-294: Determination of JAK2V617F allele burden in a phase II study of patients with myelofibrosis treated with SAR302503 using a sensitive and robust allele-specific qPCR assay.** April 9<sup>th</sup>,2013

- Adrian S Dobs, Ralph V Boccia, Christopher C Croot, **Nashat Y Gabrail**, James T Dalton, Michael L Hancock, Mary A Johnston, Mitchell S Steiner: **Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial.** *The Lancet*. Volume 14: Number 4. Pg 335-345. April 2013
- **Nashat Y. Gabrail**, Carrie L. Smith; **Gabrail Cancer Center, Canton, Ohio: Preliminary evidence of activity of Pralatrexate in relapsed/refractory Ovarian Cancer.** ASCO 2012, Abstract#15557; *J Clin Oncol* 30, 2012 (suppl; abstr e15557). June 2012
- Veena Charu<sup>1</sup>, Rebecca Clark-Snow<sup>2</sup>, **Nashat Gabrail**<sup>3</sup>, Ronald Yanagihara<sup>4</sup>, Martin J. Rosenberg<sup>5</sup>, Erin O'Boyle<sup>6</sup>, John Barr<sup>6</sup> <sup>1</sup>Pacific Cancer Medical Center, Inc., Anaheim, CA; <sup>2</sup>University of Kansas Cancer Center, Westwood, KS; <sup>3</sup>**Gabrail Cancer Center, Canton, OH**; <sup>4</sup>Ronald Yanagihara, MD, Gilroy, CA; <sup>5</sup>MAJARO InfoSystems, Santa Clara, CA; <sup>6</sup>A.P.Pharma, Redwood City,CA, USA: **Patient Satisfaction with Control of Emesis Following Chemotherapy: Comparison of APF530, a Subcutaneous Extended-Release Formulation of Granisetron, Versus Intravenous Palonosetron.** MASCC, Poster, June 2012
- Ravi Vij<sup>1</sup>, Michael Wang<sup>2</sup>, Jonathan L. Kaufman<sup>3</sup>, Sagar Lonial<sup>3</sup>, Andrzej J. Jakubowiak<sup>4</sup>, A. Keith Stewart<sup>5</sup>, Vishal Kukreti<sup>6</sup>, Sundar Jagannath<sup>7</sup>, Kevin T. McDonagh<sup>8</sup>, Melissa Alsina<sup>9</sup>, Nizar J. Bahlis<sup>10</sup>, Frederic J. Reu<sup>11</sup>, **Nashat Y. Gabrail**<sup>12</sup>, Andrew Belch<sup>13</sup>, Jeffrey V. Matous<sup>14</sup>, Peter Lee<sup>15</sup>, Peter Rosen<sup>16</sup>, Michael Sebag<sup>17</sup>, David H. Vesole<sup>18</sup>, Lori A. Kunkel<sup>19</sup>, Sandra M. Wear<sup>20</sup>, Alvin F. Wong<sup>21</sup>, Robert Z. Orłowski<sup>2</sup>, and David S. Siegel<sup>18</sup>; <sup>1</sup>Washington University School of Medicine, St Louis, MO; <sup>2</sup>MD Anderson Cancer Center, Houston, TX; <sup>3</sup>Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; <sup>4</sup>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; <sup>5</sup>Mayo Clinic, Scottsdale, AZ; <sup>6</sup>University of Toronto Princess Margaret Hospital, Toronto, ON; <sup>7</sup>Mount Sinai Medical Center, New York, NY; <sup>8</sup>University of Kentucky College of Medicine, Lexington, KY; <sup>9</sup>H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL; <sup>10</sup>Tom Baker Cancer Centre, University of Calgary, Calgary, AB; <sup>11</sup>Taussig Cancer Center, Cleveland Clinic, Cleveland, OH; <sup>12</sup>**Gabrail Cancer Center, Canton, OH**; <sup>13</sup>University of Alberta Cross Cancer Institute, Edmonton, AB; <sup>14</sup>Colorado Blood Cancer Institute, Denver, CO; <sup>15</sup>Tower Cancer Research Foundation, Beverly Hills, CA; <sup>16</sup>Roy and Patricia Disney Family Cancer Center, Providence Saint Joseph Medical Center, Burbank, CA; <sup>17</sup>Royal Victoria Hospital, Montreal, QC; <sup>18</sup>John Theurer Cancer Center at Hackensack University, Hackensack, NJ; <sup>19</sup>Independent consultant, San Francisco, CA; <sup>20</sup>Multiple Myeloma Research Consortium, Norwalk, CT; and <sup>21</sup>Onyx Pharmaceuticals, South San Francisco, CA: **An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma.** *Blood*. Volume 119: June 14 2012
- Razelle Kurzrock<sup>1</sup>, **Nash Gabrail**<sup>4</sup>, Chandtip Chandhasin<sup>1</sup>, Stacy Moulder<sup>2</sup>, Carrie Smith<sup>4</sup>, Andrew Brenner<sup>3</sup>, Kamallesh Sankhala<sup>3</sup>, Alain Mita<sup>3</sup>, Kelly Elian<sup>5</sup>, Danielle Bouchard<sup>5</sup>, and John Sarantopoulos<sup>3</sup>, Departments of <sup>1</sup>Investigational Cancer Therapeutics (Phase I Program) and <sup>2</sup>Breast Medical Oncology, MD Anderson Cancer Center, Houston, Texas; <sup>3</sup>Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio, San Antonio, Texas; <sup>4</sup>**Gabrail Cancer Center, Canton, Ohio**; and <sup>5</sup>Angiochem Inc., Montreal, Québec, Canada: **Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors.** *Molecular Cancer Therapeutics*, February 2012
- Alexander Spira<sup>1</sup>, Nicholas Iannotti<sup>2</sup>, Michael Savin<sup>3</sup>, Marcus Neubauer<sup>4</sup>, **Nashat Gabrail**<sup>5</sup>, Ronald Yanagihara<sup>6</sup>, Edith Zang<sup>7</sup>, Patricia Cole<sup>7</sup>, Dale Shuster<sup>7</sup>, Asha Das<sup>7</sup> <sup>1</sup>Virginia Cancer Specialists, Fairfax, VA, <sup>2</sup>Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, FL, <sup>3</sup>Texas Oncology, Texas Cancer Center at Medical City, Dallas, TX, <sup>4</sup>Kansas City Cancer Center, Kansas City, MO, <sup>5</sup>Gabrail Cancer Center, Canton, OH, <sup>6</sup>St Louise Hospital, Gilroy, CA, <sup>7</sup>Eisai Inc., Woodcliff Lake, NJ: **A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non-Small-Cell Lung Cancer.** *Clinical Lung Cancer*. Volume 13: Issue 1. Pages 31-38. January 2012

- Lowell B. Anthony, MD,<sup>1</sup> **Nashat Y. Gabrail, MD,**<sup>2</sup> Hassan Ghazal, MD,<sup>3</sup> Donald V. Woytowitz, MD,<sup>4</sup> Marshall S. Flam, MD,<sup>5</sup> Anibal Drelichman, MD,<sup>6</sup> David M. Loesch, MD,<sup>7</sup> Demi A. Niforos, MS,<sup>8</sup>, and Antoinette Mangione, MD, PharmD<sup>9</sup>; for the Iron Sucrose Study Group\*; (1) Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA; (2) Nashat Cancer Center, Canton, OH; (3) Kentucky Cancer Clinic, Hazard, KY; (4) Florida Cancer Specialists, Fort Myers, FL; (5) Hematology/Oncology Group of Fresno, Fresno, CA; (6) Newland Medical Associates, Southfield, MI; (7) Oncology/Hematology Associates, Indianapolis, IN; (8) AAI Pharma, Inc., Natick, MA; and (9) Luitpold Pharmaceuticals/American Regent, Inc., Norristown, PA: **IV iron sucrose for cancer and/or chemotherapy-induced anemia in patients treated with erythropoiesis stimulating agents.** *Community Oncology*. Manuscript; June 29, 2011
- Stewart,<sup>1</sup> JL Kaufman,<sup>2</sup> AJ Jakubowiak,<sup>3</sup> S Jagannath,<sup>4</sup> V Kukreti,<sup>5</sup> KT McDonagh,<sup>6</sup> M Alsina,<sup>7</sup> NJ Bahlis,<sup>8</sup> A Belch,<sup>9</sup> FJ Reu,<sup>10</sup> **NY Gabrail,**<sup>11</sup> J Matous,<sup>12</sup> DH Vesole,<sup>13</sup> RZ Orłowski,<sup>14</sup> L Kunkel,<sup>15</sup> NR Sacks,<sup>16</sup> P Lee,<sup>17</sup> M Sebag,<sup>18</sup> M Wang,<sup>14</sup> R Vij,<sup>19</sup> The Multiple Myeloma Research Consortium<sup>20</sup>; <sup>1</sup>Mayo Clinic, Scottsdale, AZ; <sup>2</sup>Winship Cancer Institute, Atlanta, GA; <sup>3</sup>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; <sup>4</sup>Mt. Sinai Medical Center, New York, NY; <sup>5</sup>Princess Margaret Hospital, Toronto, ON, Canada; <sup>6</sup>University of Kentucky College of Medicine, Lexington, KY; <sup>7</sup>H. Lee Moffitt Cancer Center, Tampa, FL; <sup>8</sup>Tom Baker Cancer Centre, Calgary, AB, Canada; <sup>9</sup>University of Alberta Cross Cancer Institute, Edmonton, AB, Canada; <sup>10</sup>Cleveland Clinic, Cleveland, OH; <sup>11</sup>**Gabrail Cancer Center, Canton, OH;** <sup>12</sup>Rocky Mountain Cancer Center, Denver, CO; <sup>13</sup>John Theurer Cancer CeHackensack, NJ; <sup>14</sup>MD Anderson Cancer Center, Houston, TX; <sup>15</sup>Independent Consultant, San Francisco, CA; <sup>16</sup>Onyx Pharmaceuticals, South San Francisco, CA; <sup>17</sup>Tower Cancer Research Foundation, Beverly Hills, CA; <sup>18</sup>Royal Victoria Hospital, Montreal, QC, Canada; <sup>19</sup>Washington University School of Medicine, St. Louis, MO; <sup>20</sup>Norwalk, CT: **Carfilzomib produces a high single-agent response rate in patients with bortezomib-naïve relapsed multiple myeloma: Updated interim results from the PX-171-004 study**AK. 47<sup>th</sup> American Society of Clinical Oncology Annual Meeting; June 3–7, 2011; Chicago, IL
- M Wang,<sup>1</sup> W Bensinger,<sup>2</sup> T Martin,<sup>3</sup> M Alsina,<sup>4</sup> D Siegel,<sup>5</sup> **N Gabrail,**<sup>6</sup> P Hari,<sup>7</sup> S Singhal,<sup>8</sup> R Vescio,<sup>9</sup> S Assouline,<sup>10</sup> L Kunkel,<sup>11</sup> M Vallone,<sup>12</sup> A Wong,<sup>12</sup> R Niesvizky<sup>13</sup> <sup>1</sup>MD Anderson Cancer Center, Houston, TX; <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, WA; <sup>3</sup>University of California, San Francisco, CA; <sup>4</sup>H. Lee Moffitt Cancer Center, Tampa, FL; <sup>5</sup>John Theurer Cancer Center, Hackensack, NJ; <sup>6</sup>**Gabrail Cancer Center, Canton, OH;** <sup>7</sup>Medical College of Wisconsin, Milwaukee, WI; <sup>8</sup>Northwestern University School of Medicine, Chicago, IL; <sup>9</sup>Cedars Sinai Medical Center, Los Angeles, CA; <sup>10</sup>Jewish General Hospital, Montreal, QC, Canada; <sup>11</sup>Independent Consultant, San Francisco, CA; <sup>12</sup>Onyx Pharmaceuticals, Inc., South San Francisco, CA; <sup>13</sup>Weill Cornell Medical College, New York, NY: **Interim results from PX-171-006, a phase 2 multicenter dose-expansion study of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed and/or refractory multiple myeloma.** 47<sup>th</sup> American Society of Clinical Oncology Annual Meeting; June 3–7, 2011; Chicago, IL
- Alberto Bessudo<sup>1</sup>, Johanna C. Bendell<sup>2</sup>, **Nashat Y. Gabrail**<sup>3</sup>, Mikhail V. Kopp<sup>4</sup>, Lothar Muller<sup>5</sup>, Lowell L. Hart<sup>6</sup>, Vladimir I. Vladimirov<sup>7</sup>, Amitkumar U. Pande<sup>8</sup>, Igor Gorbachevsky<sup>8</sup>, Cathy Eng<sup>9</sup> <sup>1</sup>Pacific Oncology Hematology Associates, Encinitas, CA; <sup>2</sup>Sarah Cannon Research Institute, Nashville, TN; <sup>3</sup>**Gabrail Cancer Center, Canton, OH;** <sup>4</sup>Samara Regional Clinical Oncology Dispensary, Samara, Russia; <sup>5</sup>Onkologische Schwerpunktpraxis Leer-Emden, Leer, Germany; <sup>6</sup>Florida Cancer Specialists, Fort Myers, FL; <sup>7</sup>State Medical Institution Pyatigorsk, Pyatigorsk, Russia; <sup>8</sup>Daiichi Sankyo, Inc., Edison, NJ; <sup>9</sup>University of Texas M. D. Anderson Cancer Center, Houston, TX: **Phase I Results of the Randomized, Placebo-Controlled, Phase I/II Study of the Novel Oral C-MET Inhibitor, Tivantinib (ARQ 197), Irinotecan (CPT-11), and Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer Who Have Received Front-line Systemic Therapy.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois
- <sup>1</sup>Ruben Niesvizky, <sup>2</sup>Ian Flinn, <sup>3</sup>Robert Rifkin, <sup>4</sup>**Nashat Gabrail,** <sup>5</sup>Veena Charu, <sup>6</sup>Billy Clowney, <sup>7</sup>James Essell, <sup>8</sup>Yousuf Gaffar, <sup>9</sup>Thomas Warr, <sup>10</sup>Rachel Neuwirth, <sup>10</sup>Deyanira Corzo, <sup>11</sup>James Reeves; <sup>1</sup>Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, <sup>2</sup>Sarah Cannon Research Institute, Nashville, TN, USA, <sup>3</sup>Rocky Mountain Cancer Center, US Oncology, Denver, CO, USA, <sup>4</sup>**Gabrail Cancer Center, Canton, OH, USA,** <sup>5</sup>Pacific Cancer Medical Center, Anaheim, CA, USA, <sup>6</sup>Santee Hematology/Oncology, Sumter, SC, USA, <sup>7</sup>Oncology

Hematology Care Inc., Cincinnati, OH, USA, <sup>8</sup>St. Joseph Medical Center, Towson, MD, USA, <sup>9</sup>Clinic Cancer Care, Great Falls, MT, USA, <sup>10</sup>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, <sup>11</sup>Florida Cancer Specialists, Fort Myers, FL, USA: **Analysis of Response, PFS, and Safety After Bortezomib-Based Induction Regimens and Weekly Bortezomib Maintenance Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients (pts) Ineligible for Transplant in the Phase 3b UPFRONT Study.** International Myeloma Workshop, May 3-6 2011, Paris, France

- E.B. Garon<sup>1</sup>, F. Kabbinavar<sup>1</sup>, J. Neidhart<sup>2</sup>, J. D. Neidhart<sup>2</sup>, **N. Gabrail**<sup>3</sup>, M. Ribeiro de Oliveira<sup>4</sup>, SP. Lu<sup>5</sup>, J. Balkissoon<sup>5</sup>; <sup>1</sup>UCLA Medical Center, Los Angeles, CA; <sup>2</sup>San Juan Oncology Associates, Farmington, NM; <sup>3</sup>**Gabrail Cancer Center; Canton, OH**; <sup>4</sup>Northwest Medical Specialties, Tacoma, WA; <sup>5</sup>OXiGENE, Inc., South San Francisco, CA: **Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Analyses of Safety and Efficacy of the FALCON Trial.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois
- R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris, E. A. Sausville, E. Kutarska, S. A. Ghamande, **N. Y. Gabrail**, S. De Pasquale, E. Nowara, L. Gilbert, J. R. Caton, R. H. Gersh, M. G. Teneriello, W. A. Harb, P. Konstantinopoulos, J. T. Symanowski, C. Lovejoy, R. A. Messmann; Blumenthal Cancer Center Carolinas Medical Center, Charlotte, NC; University of Texas M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Columbia University Cancer Center, New York, NY; Karmanos Cancer Institute/Wayne State University, Detroit, MI; University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, MD; Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland; Medical College of Georgia, Augusta, GA; **Gabrail Cancer Center, Canton, OH**; Chattanooga's Program in Women's Oncology, Chattanooga, TN; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; McGill University Health Centre, Montreal, QC, Canada; Willamette Valley Cancer Center, Eugene, OR; Cancer Center of Northwest, Spokane, WA; US Oncology, The Woodlands, TX; Horizon Oncology Center, Lafayette, IN; Beth Israel Deaconess Medical Center, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Endocyte, Inc., West Lafayette, IN: **PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois, *J Clin Oncol* 29: 2011 (suppl; abstr 5045). June 2011
- K. Ankrom, C.L. Smith, **N.Y. Gabrail**; Mount Union University, Alliance, OH; **Gabrail Cancer Center, Canton, OH: Incidence of Radiation recall in a community cancer center.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois. *J Clin Oncol* 29: 2011 (suppl; abstr e19640) June 2011
- <sup>1</sup>**N. Y. Gabrail**, <sup>2</sup>S. M. Weinstein, <sup>3</sup>A. W. Burton; <sup>1</sup>**Gabrail Cancer Center, Canton, OH**; <sup>2</sup>Huntsman Cancer Institute, <sup>3</sup>University of Utah, Salt Lake City, UT; University of Texas M. D. Anderson Cancer Center, Houston, TX: **Long-term nasal tolerability of fentanyl pectin nasal spray in breakthrough pain in cancer.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois, *J Clin Oncol* 29: 2011 (suppl; abstr e19604) June 2011
- <sup>1</sup>David B. Agus, <sup>2</sup>Walter M. Stadler, <sup>3</sup>Daniel Shevrin, <sup>4</sup>John Gullo, <sup>5</sup>Lowell Hart, <sup>6</sup>Gary R. MacVicar, <sup>7</sup>Omid Hamid, <sup>8</sup>**Nashat Gabrail**, <sup>9</sup>John Hainsworth, <sup>10</sup>Mitchell Gross, <sup>11</sup>Jingyuan Wang, <sup>11</sup>Laura DeLeon, <sup>12</sup>David MacLean, and Robert Dreicer; <sup>1</sup>University of Southern California Keck School of Medicine, <sup>2</sup>University of Chicago Medical Center, <sup>3</sup>NorthShore University HealthSystem, <sup>4</sup>Hematology/Oncology Associates, <sup>5</sup>Florida Cancer Specialists, <sup>6</sup>Northwestern University Feinberg School of Medicine, <sup>7</sup>The Angeles Clinic & Research Institute, <sup>8</sup>**Gabrail Cancer Center**, <sup>9</sup>Sarah Cannon Cancer Research Institute, <sup>10</sup>Westside Prostate Cancer Center, <sup>11</sup>Millennium Pharmaceuticals Inc, <sup>12</sup>Cleveland Clinic: **Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase 1/2 study.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois, June 2011
- M. J. Higgins, **N. Y. Gabrail**, K. Miller, S. V. Agresta, S. Sharma, C. McDonagh, J. Murray, K. Andreas, S. Frye, V. M. Moyo, C. Niyikiza, P. D. Ryan; Massachusetts General Hospital, Boston, MA; **Gabrail Cancer Center, Canton, OH**; Indiana University Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Cambridge, MA; Huntsman Cancer Institute, Salt Lake City, UT: **A phase I/II study of**

**MM-111, a novel bispecific antibody that targets the ErbB2/ErbB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois. *J Clin Oncol* 29: 2011 (suppl; abstr TPS119). Poster. June 2011

- G. J. Riely, S. N. Gettinger, R. G. Stoller, **N. Y. Gabrail**, G. K. Dy, G. J. Weiss, C. Tunkey, G. Skliris, S. Strychor, J. Dunbar, D. DeLucia, R. W. Ross, J. E. Gray; Memorial Sloan-Kettering Cancer Center, New York, NY; Yale University School of Medicine, New Haven, CT; University of Pittsburgh Cancer Center, Pittsburgh, PA; **Gabrail Cancer Center, Canton, OH**; Roswell Park Cancer Institute, Buffalo, NY; Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ; Infinity Pharmaceuticals, Inc., Cambridge, MA; University of Pittsburgh, Pittsburgh, PA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL: **Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois. *J Clin Oncol* 29: 2011 (suppl; abstr 7516), Poster, June 2011
- DS Siegel,<sup>1</sup> JL Kaufman,<sup>2</sup> M Wang,<sup>3</sup> T Martin,<sup>4</sup> S Jagannath,<sup>5</sup> R Niesvizky,<sup>6</sup> FJ Reu,<sup>7</sup> M Alsina,<sup>8</sup> A Badros,<sup>9</sup> **NY Gabrail**,<sup>10</sup> V Kukreti,<sup>11</sup> S Singhal,<sup>12</sup> D Kotlovker,<sup>13</sup> D Bomba,<sup>13</sup> AL Hannah,<sup>13</sup> R Vij<sup>14</sup>; <sup>1</sup>John Theurer Cancer Center, Hackensack, NJ, USA; <sup>2</sup>Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; <sup>3</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>4</sup>University of California San Francisco, San Francisco, CA, USA; <sup>5</sup>Mount Sinai Medical Center, New York, NY, USA; <sup>6</sup>Weill Cornell Medical College, New York, NY, USA; <sup>7</sup>Taussig Cancer Center - Cleveland Clinic, Cleveland, OH, USA; <sup>8</sup>H. Lee Moffitt Cancer Center, Tampa, FL, USA; <sup>9</sup>University of Maryland Greenebaum Cancer Center, Baltimore MD, USA; <sup>10</sup>**Gabrail Cancer Center, Canton, OH, USA**; <sup>11</sup>Princess Margaret Hospital, Toronto, ON, Canada; <sup>12</sup>Northwestern University School of Medicine, Chicago, IL, USA; <sup>13</sup>Onyx Pharmaceuticals, South San Francisco, CA, USA; <sup>14</sup>Washington University School of Medicine, St. Louis, MO, USA: **A summary of safety data achieved with long-term carfilzomib treatment in patients with relapsed and/or refractory multiple myeloma.** 16th Congress of European Hematology Association;; London, UK. June 9–12, 2011
- **Nashat Gabrail, MD**<sup>1</sup>, Eric Sandler, MD<sup>2</sup>, Veena Charu, MD<sup>3</sup>, Nick Anas, MD<sup>4</sup>, Eduardo Lim, MD<sup>5</sup>, Martha Blaney, PharmD<sup>6</sup>, Mark Ashby, PhD<sup>6</sup>, Barbara Gillespie, MD<sup>7</sup>, Susan Begelman, MD<sup>6</sup> **Gabrail Cancer Center , Canton, OH**, <sup>2</sup>Nemours Children’s Clinic, Jacksonville, FL, <sup>3</sup>Pacific Cancer Medical Center, Inc Anaheim, CA, <sup>4</sup>Children’s Hospital of Orange County, Orange, CA, <sup>5</sup>Private Practice, Los Angeles, CA, <sup>6</sup>Genetech, Inc South San Francisco, CA, <sup>7</sup>Quintiles, Inc., Morrisville, NC: **TROPICS 1: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters.** *Journal of Vascular and Interventional Radiology*. Volume 21: Issue 12. Pages 1852-1858. December 2010
- Russell K. Portenoy<sup>a</sup>, Allen W. Burton<sup>b</sup>, **Nashat Gabrail**<sup>c</sup>, Donald Taylor<sup>d</sup>, on behalf of the Fentanyl Pectin Nasal Spray 043 Study Group, <sup>a</sup> Beth Israel Medical Center, New York, NY, USA, <sup>b</sup> The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, <sup>c</sup> **Gabrail Cancer Center, Canton, OH, USA**, <sup>d</sup> Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, GA, USA: **A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.** *Pain* Volume 151: Issue 3 Pages 617-624. December 2010
- Ruben Niesvizky<sup>1</sup>, Ian Flinn<sup>2</sup>, Robert Rifkin<sup>3</sup>, **Nashat Gabrail**<sup>4</sup>, Veena Charu<sup>5</sup>, Billy Clowney<sup>6</sup> James Essell<sup>7</sup>, Yousuf Gaffar<sup>8</sup>, Thomas Warr<sup>9</sup>, Rachel Neuwirth<sup>10</sup>, Deyanira Corzo<sup>10</sup>, and James Reeves<sup>11</sup> Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY; <sup>2</sup>Sarah Cannon Research Institute, Nashville, TN; <sup>3</sup>Rocky Mountain Cancer Center, US Oncology, Denver, CO; <sup>4</sup>**Gabrail Cancer Center, Canton, OH**; <sup>5</sup>Pacific Cancer Medical Center, Anaheim, CA; <sup>6</sup>Santee Hematology/Oncology, Sumter, SC; <sup>7</sup>Oncology Hematology Care Inc., Cincinnati, OH; <sup>8</sup>Alliance Hematology Oncology, Westminster, MD; <sup>9</sup>Clinic Cancer Care, Great Falls, MT; <sup>10</sup>Millennium Pharmaceuticals, Inc., Cambridge, MA; <sup>11</sup>Florida Cancer Specialists, Bonita Springs, FL: **Patient-Reported Quality of Life in Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results from the Phase 3b UPFRONT Study.** ASH; Abstract #3026. Poster. December, 2010
- Ruben Niesvizky<sup>1</sup>, Ian Flinn<sup>2</sup>, Robert Rifkin<sup>3</sup>, **Nashat Gabrail**<sup>4</sup>, Veena Charu<sup>5</sup>, Billy Clowney<sup>6</sup>, James

Essell<sup>7</sup>, Yousuf Gaffer<sup>8</sup>, Thomas Warr<sup>9</sup>, Rachel Neuwirth<sup>10</sup>, Deyanira Corzo<sup>10</sup>, and James Reeves<sup>11</sup>; <sup>1</sup>Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY; <sup>2</sup>Sarah Cannon Research Institute, Nashville, TN; <sup>3</sup>Rocky Mountain Cancer Center, US Oncology, Denver, CO; <sup>4</sup>**Gabrail Cancer Center, Canton, OH**; <sup>5</sup>Pacific Cancer Medical Center, Anaheim, CA; <sup>6</sup>Santee Hematology/Oncology, Sumter, SC; <sup>7</sup>Oncology Hematology Care Inc., Cincinnati, OH; <sup>8</sup>Carroll County Cancer Center, Westminster, MD; <sup>9</sup>Clinic Cancer Care, Great Falls, MT; <sup>10</sup>Millennium Pharmaceuticals, Inc., Cambridge, MA; <sup>11</sup>Florida Cancer Specialists, Fort Myers, FL: **Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.** ASH, Abstract # 619. Poster. December, 2010

- Ravi Vij, MBBS, MD<sup>1</sup>, Jonathan L. Kaufman, MD<sup>2</sup>, Andrzej J Jakubowiak, MD, PhD<sup>3</sup>, A. Keith Stewart, MBChB<sup>4</sup>, Sundar Jagannath, MD<sup>5</sup>, Vishal Kukreti, MD, FRCPC<sup>6</sup>, Kevin T. McDonagh, MD<sup>7</sup>, Melissa Alsina, MD<sup>8</sup>, Nizar J Bahlis, MD<sup>9</sup>, Andrew Belch, MD<sup>10</sup>, Frederic J. Reu, MD<sup>11</sup>, **Nashat Y Gabrail, MD<sup>12</sup>**, Jeffrey Matous, MD<sup>13</sup>, David H. Vesole, MD, PhD<sup>14</sup>, Robert Z. Orlowski, MD, PhD<sup>15</sup>, Mai H. Le, MD<sup>16</sup>, Peter Lee, MD, PhD<sup>17</sup>, Michael Wang, MD<sup>18</sup> and The Multiple Myeloma Research Consortium (MMRC)<sup>19</sup>; <sup>1</sup>Division of Oncology, Washington University School of Medicine, Saint Louis, MO; <sup>2</sup>Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; <sup>3</sup>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; <sup>4</sup>Mayo Clinic in Arizona, Scottsdale, AZ; <sup>5</sup>Multiple Myeloma Program, Mount Sinai Medical Center, New York, NY; <sup>6</sup>Div. of Hematology/Oncology, Princess Margaret Hospital, Toronto, ON, Canada; <sup>7</sup>University of Kentucky, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY; <sup>8</sup>H. Lee Moffitt Cancer Center, Tampa, FL; <sup>9</sup>Division of Hematology, University of Calgary, Calgary, AB, Canada; <sup>10</sup>Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; <sup>11</sup>Taussig Cancer Center, Cleveland, OH; <sup>12</sup>**Gabrail Cancer Center Research, Canton, OH**; <sup>13</sup>Rocky Mountain Cancer Ctr., Denver, CO; <sup>14</sup>Hackensack University Medical Center, Hackensack, NJ; <sup>15</sup>Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX; <sup>16</sup>Clinical Development, Onyx Pharmaceuticals, Emeryville, CA; <sup>17</sup>Tower Cancer Research Foundation, Beverly Hills, CA; <sup>18</sup>MD Anderson Cancer Center, Houston, TX; <sup>19</sup>The Multiple Myeloma Research Consortium, Norwalk, CT: **Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even in High-risk Patients.** ASH, Abstract #1938. Poster. December 4, 2010
- Sundar Jagannath, MD<sup>1</sup>, Ravi Vij, MBBS, MD<sup>2</sup>, Jonathan L. Kaufman, MD<sup>3</sup>, Thomas Martin, MD<sup>4</sup>, Ruben Niesvizky, MD<sup>5</sup>, **Nashat Y Gabrail MD<sup>6</sup>**, Melissa Alsina, MD<sup>7</sup>, Alvin Wong PharmD<sup>8</sup>, Mai H. Le, MD<sup>9</sup>, Leanne McCulloch, PharmD<sup>8</sup>, Alison Hannah, MD<sup>8</sup>, Michael Kauffman, MD, PhD<sup>8</sup> and Samuel diCapua Siegal, MD, PHD<sup>10</sup>; <sup>1</sup>Multiple Myeloma Program, Mount Sinai Medical Center, New York, NY, USA, <sup>2</sup>Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA, <sup>3</sup>Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA, <sup>4</sup>University of San Francisco, San Francisco, <sup>5</sup>Medicine and Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA, <sup>6</sup>**Gabrail Cancer Center Research, Canton, OH, USA**, <sup>7</sup>Blood and Marrow Transplant, H. Lee Moffitt Cancer Center, Tampa, FL, USA, <sup>8</sup>Onyx Pharmaceuticals, Emeryville, CA, USA, <sup>9</sup>Clinical Development, Onyx Pharmaceuticals, Emeryville, CA, USA, <sup>10</sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA: **Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM).** ASH, Abstract #1953. Poster. December 4<sup>th</sup>, 2010
- Michael Wang <sup>1</sup> Ruben Niesvizky <sup>2</sup> Robert Orlowski <sup>1</sup> Melissa Alsina <sup>3</sup> Tom Martin <sup>4</sup> Seema Singhal <sup>5</sup> **Nashat Gabrail <sup>6</sup>** Marcy Vallone <sup>7</sup> Lynne A. Bui <sup>7</sup> Michael Kauffman <sup>7</sup> William Bensinger <sup>8</sup> (1) MD Anderson Cancer Center, Houston, TX (2) Weill Cornell Medical College, New York, NY (3) H. Lee Moffitt Cancer Center, Tampa, FL (4) UCSF, San Francisco, CA (5) Northwestern University School of Medicine, Chicago, IL (6) **Gabrail Cancer Center, Canton, OH** (7). Onyx Pharmaceuticals, Emeryville, CA (8) Fred Hutchinson Cancer Research Center, Seattle, WA: **Phase 1b Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).** Lymphoma & Myeloma 2010. Abstract # 37.00. Poster. October 21-23, 2010
- Tom Martin <sup>1</sup> Ruben Niesvizky <sup>2</sup> Michael Wang <sup>3</sup> Robert Orlowski <sup>3</sup> Melissa Alsina <sup>4</sup> Seema Singhal <sup>5</sup> **Nashat Gabrail <sup>6</sup>** Marcy Vallone <sup>7</sup> Lynne Bui <sup>7</sup> Michael Kauffman <sup>7</sup> William Bensinger <sup>8</sup>; 1. UCSF, San Francisco, CA 2. Weill Cornell Medical College, New York, NY 3. MD Anderson Cancer Center, Houston,

TX 4. H. Lee Moffitt Cancer Center, Tampa, FL 5. Northwestern University School of Medicine, Chicago, IL 6. **Gabraail Cancer Center, Canton, OH** 7. Onyx Pharmaceuticals, Emeryville, CA 8. Fred Hutchinson Cancer Research Center, Seattle, WA: **Phase 2 Multicenter Dose Expansion Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)**. Lymphoma & Myeloma 2010. Abstract # 41.00. Poster. October 21-23, 2010

- David Siegel,<sup>1</sup> Michael Wang,<sup>2</sup> Jonathan Kaufman,<sup>3</sup> Andrzej Jakubowiak,<sup>4</sup> Sundar Jagannath,<sup>5</sup> A. Keith Stewart,<sup>6</sup> Vishal Kukreti,<sup>7</sup> Kevin McDonagh,<sup>8</sup> Nizar Bahlis,<sup>9</sup> Frederic Reu,<sup>10</sup> Melissa Alsina,<sup>11</sup> **Nashat Gabrail**,<sup>12</sup> Andrew Belch,<sup>13</sup> Jeffrey Matous,<sup>14</sup> Mai H. Le,<sup>15</sup> Ravi Vij,<sup>16</sup> The Multiple Myeloma Research Consortium (MMRC)<sup>17</sup>; <sup>1</sup>Hackensack University Medical Center, Hackensack, NJ; <sup>2</sup>MD Anderson Cancer Center, Houston, TX; <sup>3</sup>Winship Cancer Institute-Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; <sup>4</sup>University of Michigan Comprehensive Cancer Center, Michigan, MI; <sup>5</sup>Mt. Sinai Medical Center, New York, NY; <sup>6</sup>Mayo Clinic, Scottsdale, AZ; <sup>7</sup>Princess Margaret Hospital, Toronto, Ontario, Canada; <sup>8</sup>University of Kentucky College of Medicine, Lexington, KY; <sup>9</sup>Tom Baker Cancer Centre, Calgary, Alberta, Canada; <sup>10</sup>Taussig Cancer Center, Cleveland Clinic, Cleveland, OH; <sup>11</sup>H. Lee Moffitt Cancer Center & Research Center, Tampa, FL; <sup>12</sup>**Gabraail Cancer Center, Canton, OH**; <sup>13</sup>University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada; <sup>14</sup>Rocky Mountain Blood and Marrow Transplant Program, Denver, CO; <sup>15</sup>Onyx Pharmaceuticals, Inc., Emeryville, CA; <sup>16</sup>Washington University School of Medicine, St. Louis, MO; <sup>17</sup>The Multiple Myeloma Research Consortium, Norwalk, CT: **Results of an Ongoing Open-label, Phase 2 Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)**. XXXIII World Congress of the International Society of Hematology -Jerusalem, Israel - October 10–13, 2010
- **Nashat Y Gabrail M.D., Gabrail Cancer Center**: Letter to the Editor. **Fighting current trends in Cancer Care**. *Oncologistics*; Volume 9:Issue 2.Summer 2010.
- William Bensinger, MD, Michael Wang, MD, Robert Z. Orlowski, MD, PhD, Melissa Alsina, MD, Tom Martin, MD, Seema Singhal, MD, **Nashat Gabrail, MD**, Marcy Vallone, Michael Kauffman, MD, PhD, Ruben Niesvizky, MD Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center, Tampa, FL; University of California San Francisco, San Francisco, CA; Northwestern University, Chicago, IL; **Gabraail Cancer Center, Canton, OH**; Onyx Pharmaceuticals, Emeryville, CA; Weill Cornell Medical College, New York, NY: **Dose Escalation Study of Carfilzomib + Lenalidomide + LowDose Dexamethasone in Relapsed/Refractory Multiple Myeloma**. ASCO 2010. June 2010
- John Sarantopoulos<sup>1</sup>, **Nashat Gabrail**<sup>2</sup>, Stacy Moulder<sup>3</sup>, Andrew Brenner<sup>1</sup>, Carrie Smith<sup>2</sup>, Danielle Bouchard<sup>4</sup>, Kelly Elian<sup>4</sup>, Betty Lawrence<sup>4</sup>, Wendy Churchill<sup>4</sup>, Paula Bento<sup>4</sup>, Dimitri Fitsialis<sup>5</sup>, Ann Neale<sup>6</sup>, Jean-Paul Castaigne<sup>4</sup>, Razelle Kurzrock<sup>3</sup> <sup>1</sup>Cancer Therapy and Research Center, San Antonio, Texas; <sup>2</sup>**Gabraail Cancer Center, Canton, Ohio**; <sup>3</sup>MD Anderson Cancer Center, Houston, Texas; <sup>4</sup>Angiochem Inc., Montreal, Québec, Canada; <sup>5</sup>Intrinsic Health Sciences Inc., Mississauga, Ontario, Canada; <sup>6</sup>WinPharm Associates, Danville, California: **ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases**. ASCO 2010. Abstract ID #2556. Poster. June 2010
- Razelle Kurzrock, MD<sup>1</sup>, **Nash Gabrail, MD**<sup>3</sup>, Chandtip Chandhasin, PhD<sup>1</sup>, Stacy Moulder, MD<sup>2</sup>, Carrie Smith, RN<sup>3</sup>, Andrew Brenner, MD, PhD<sup>4</sup>, Kamallesh Sankhala, MD<sup>4</sup>, Alain Mita, MD<sup>4</sup>, Kelly Elian, MS<sup>5</sup>, Danielle Bouchard, CCRA<sup>5</sup>, John Sarantopoulos, MD<sup>4</sup> <sup>1</sup>Department of Investigational Cancer Therapeutics (Phase I Program), <sup>2</sup>Department of Breast Medical Oncology, M. D. Anderson Cancer Center, Houston, TX; <sup>3</sup>**Gabraail Cancer Center, Canton, OH**; <sup>4</sup>Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio, San Antonio, TX; and <sup>5</sup>Angiochem Inc., Montreal (Québec), Canada: **SAFETY, PHARMACOKINETICS AND ACTIVITY OF ANG1005, A NOVEL CONJUGATE OF ANGIOPEP-2 AND PACLITAXEL, IN PATIENTS WITH ADVANCED SOLID TUMORS**. ASCO 2010. June 2010
- **N. Gabrail**<sup>1</sup>, C. Smith<sup>1</sup>, J.Fox<sup>2</sup>. <sup>1</sup>Gabraail Cancer Center, Canton, Ohio, United States, 44718 <sup>2</sup>Department of Mathematics and Science, Walsh University, North Canton, Ohio, United States, 44720: **A Unique Community Based Family Cancer Registry**. ASCO 2010, Abstract #1550; *Journal of Clinical Oncology* 28:15s, 2010 (abstr.1550) . Poster, June 2010

- J. Neidhart, J. D. Neidhart; San Juan Oncology Associates, Farmington, New Mexico; **N. Gabrail; Gabrail Cancer Center; Canton, Ohio**; M. Ribeiro de Oliveira; Northwest Medical Specialties, Tacoma, Washington; SP. Lu, J. Balkissoon; OXiGENE, South San Francisco, California; F. Kabbinavar; E. Garon; UCLA Medical Center, Los Angeles, California: **Updated activity and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial.** ASCO 2010, Poster, June 2010
- B. Garon<sup>1</sup>, F. Kabbinavar<sup>1</sup>, J. Neidhart<sup>2</sup>, J. D. Neidhart<sup>2</sup>, **N. Gabrail<sup>3</sup>**, M. Ribeiro de Oliveira<sup>4</sup>, SP. Lu<sup>5</sup>, J. Balkissoon<sup>5</sup>; <sup>1</sup>UCLA Medical Center, Los Angeles, CA; <sup>2</sup>San Juan Oncology Associates, Farmington, NM; <sup>3</sup>**Gabrail Cancer Center; Canton, OH**; <sup>4</sup>Northwest Medical Specialties, Tacoma, WA; <sup>5</sup>OXiGENE, Inc., South San Francisco, CA: **Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Early Analyses of Safety and Efficacy.** ASCO 2010. Poster. June 2010
- William Bensinger, MD,<sup>1</sup> Michael Wang, MD,<sup>2</sup> Robert Z. Orlowski, MD, PhD,<sup>2</sup> Melissa Alsina, MD,<sup>3</sup> Tom Martin, MD,<sup>4</sup> Seema Singhal, MD,<sup>5</sup> **Nashat Gabrail, MD,**<sup>6</sup> Marcy Vallone,<sup>7</sup> Michael Kauffman, MD, PhD,<sup>7</sup> Ruben Niesvizky, MD<sup>8</sup>; <sup>1</sup>Fred Hutchinson Cancer Research Center, Seattle, WA; <sup>2</sup>MD Anderson Cancer Center, Houston, TX; <sup>3</sup>H. Lee Moffitt Cancer Center, Tampa, FL; <sup>4</sup>University of California San Francisco, San Francisco, CA; <sup>5</sup>Northwestern University, Chicago, IL; <sup>6</sup>**Gabrail Cancer Center, Canton, OH**; <sup>7</sup>Onyx Pharmaceuticals, Emeryville, CA; <sup>8</sup>Weill Cornell Medical College, New York, NY: **Dose-escalation Study of Carfilzomib + Lenalidomide + Low-dose Dexamethasone in Relapsed/Refractory Multiple Myeloma.** ASCO 2010. Abstract #8029. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 8029). June 2010
- **Nashat Gabrail,**<sup>1</sup> Allen Burton,<sup>2</sup> Lukas Radbruch,<sup>3</sup> Donald Taylor,<sup>4</sup> Evangeline Reyes,<sup>5</sup> and Russell Portenoy<sup>6</sup> on behalf of the Fentanyl Nasal Spray Study 045 Investigators Group <sup>1</sup>**Gabrail Cancer Center, Canton, Ohio, USA;** <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; <sup>3</sup>RWTH Aachen University, Aachen, Germany; <sup>4</sup>Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, Georgia, USA; <sup>5</sup>Compassionate Cancer Care Medical Group, Inc., Riverside, California, USA; <sup>6</sup>Beth Israel Medical Center, New York, New York, USA: **Long-term Safety, Tolerability, and Acceptability of Fentanyl Pectin Nasal Spray in the Treatment of Breakthrough Cancer Pain.** ASCO 2010. Poster. June 2010
- John Sarantopoulos<sup>1</sup>, **Nashat Gabrail**<sup>2</sup>, Stacy Moulder<sup>3</sup>, Andrew Brenner<sup>1</sup>, Carrie Smith<sup>2</sup>, Danielle Bouchard<sup>4</sup>, Kelly Elian<sup>4</sup>, Betty Lawrence<sup>4</sup>, Wendy Churchill<sup>4</sup>, Paula Bento<sup>4</sup>, Dimitri Fitsialos<sup>5</sup>, Ann Neale<sup>6</sup>, Jean-Paul Castaigne<sup>4</sup>, Razelle Kurzrock<sup>3</sup>; <sup>1</sup>Cancer Therapy and Research Center, San Antonio, Texas; <sup>2</sup>**Gabrail Cancer Center, Canton, Ohio;** <sup>3</sup>MD Anderson Cancer Center, Houston, Texas; <sup>4</sup>Angiochem Inc., Montreal, Québec, Canada; <sup>5</sup>Intrinsic Health Sciences Inc., Mississauga, Ontario, Canada; <sup>6</sup>WinPharm Associates, Danville, California: **ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.** ASCO 2010. Poster. June 2010
- **A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in central venous catheters: TROPICS 1;** oral presentation at the 2010 SIR Annual Scientific Meeting in Tampa, Florida, May 2010.
- Ruben Niesvizky,<sup>1</sup> James Reeves,<sup>2</sup> Ian Flinn,<sup>3</sup> **Nashat Gabrail,**<sup>4</sup> Robert Rifkin,<sup>5</sup> Veena Charu,<sup>6</sup> Billy Clowney,<sup>7</sup> James Essell,<sup>8</sup> Thomas Warr,<sup>9</sup> Rachel Neuwirth,<sup>10</sup> Deyanira Corzo,<sup>10</sup> on behalf of the UPFRONT Study Group <sup>1</sup>Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY; <sup>2</sup>Florida Cancer Specialists, Bonita Springs, FL; <sup>3</sup>Sarah Cannon Research Institute, Nashville, TN; <sup>4</sup>**Gabrail Cancer Center, Canton, OH;** <sup>5</sup>Rocky Mountain Cancer Centers, US Oncology, Denver, CO; <sup>6</sup>Pacific Cancer Medical Center, Anaheim, CA; <sup>7</sup>Santee Hematology/Oncology, Sumter, SC; <sup>8</sup>Oncology Hematology Care Inc., Cincinnati, OH; <sup>9</sup>Clinic Cancer Care, Great Falls, MT; <sup>10</sup>Millennium Pharmaceuticals, Inc., Cambridge, MA: **Phase 3b UPFRONT Study: Interim Results from a Community-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.** EHA. Poster. May 25, 2010

- Natasha B. Leigh<sup>1</sup>, Luis Raez<sup>2</sup>, Benjamin Besse<sup>3</sup>, Peter J. Rosen<sup>4</sup>, Fabrice Barlesi<sup>5</sup>, E. Massarelli<sup>6</sup>, **Nashat Gabrail**<sup>7</sup>, Lowell L. Hart<sup>8</sup>, Kathy S. Albain<sup>9</sup>, Lloyd Berkowitz<sup>10</sup>, Ostap Melnyk<sup>11</sup>, Frances A. Shepherd<sup>1</sup>, Lars Sternas<sup>12</sup>, Judie Ackerman<sup>12</sup>, Zhenming Shun<sup>12</sup>, Vincent A. Miller<sup>13\*</sup>, Roy S. Herbst<sup>6</sup>; <sup>1</sup> Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Canada, <sup>2</sup> University of Miami Hospital and Clinics, Miami, FL, <sup>3</sup> Institut Gustave Roussy, Villejuif, France, <sup>4</sup> Tower Cancer Research Foundation, Beverly Hills, CA, <sup>5</sup> Hopital Sainte Marguerite, Marseilles, France, <sup>6</sup> MD Anderson Cancer Center at the University of Texas, Houston, TX, <sup>7</sup> **Gabrail Cancer Center, Canton, OH**, <sup>8</sup> Florida Cancer Specialists, Fort Myers, FL, <sup>9</sup> Loyola University Medical Center, Maywood, IL <sup>10</sup> Boca Raton Community Hospital, Boca Raton, FL, <sup>11</sup> Bay Area Cancer Research Group, Concord, CA, <sup>12</sup> sanofi-aventis, Bridgewater, NJ, <sup>13</sup> Memorial Sloan-Kettering Cancer Center, New York, NY: **A Multicenter, Phase 2 Study of VEGF Trap (Aflibercept) in Platinum- and Erlotinib resistant Adenocarcinoma of the Lung.** *J Thorac Oncol.* 3 Nov 2009
- Quinn, David I.<sup>1</sup>; Nemunaitis, John<sup>2</sup>; Fuloria, Jyotsna<sup>3</sup>; Britten, Carolyn D.<sup>4</sup>; **Gabrail, Nashat**<sup>5</sup>; Yee, Lorrin<sup>6</sup>; Acharya, Milin<sup>7</sup>; Chan, Kai<sup>8</sup>; Cohen, Nadine<sup>7</sup>; Dudov, Assen<sup>9</sup>: **Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma.** *Clinical Pharmacokinetics* Volume 48: Number 3. 2009
- **N. Y. Gabrail**, A. W. Burton, E. Reyes, A. Nguyen, D. R. Taylor, on behalf of Fentanyl Nasal Spray Study 043 Investigators Group; **Gabrail Cancer Center, Canton, OH**; University of Texas M. D. Anderson Cancer Center, Houston, TX; Compassionate Cancer Care Medical Group, Inc., Riverside, CA; Compassionate Cancer Care Medical Group, Inc., Fountain Valley, CA; Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, GA: **Efficacy, tolerability, and speed of onset of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTCP): A multicenter, placebo-controlled, double-blind, two-phase crossover study.** ASCO 2009. Abstract #9535, *J Clin Oncol* 27:155, 200 (suppl abstract #9535). June 2009
- **Nashat Gabrail, MD**<sup>1</sup>, Eric Sandler, MD<sup>2</sup>, Veena Charu, MD<sup>3\*</sup>, Nick Anas, MD<sup>4\*</sup>, Eduardo Lim, MD<sup>5</sup>, Martha Blaney, PharmD<sup>6\*</sup>, Mark Ashby, PhD<sup>6\*</sup>, Barbara S Gillespie, MD<sup>7\*</sup> and Susan M Begelman, MD<sup>6\*1</sup> **Gabrail Cancer Center, Canton, OH**, <sup>2</sup>Nemours Children's Clinic, Jacksonville, FL, <sup>3</sup>Pacific Cancer Medical Center, Anaheim, CA, <sup>4</sup>Children's Hospital of Orange County, Los Angeles, CA, <sup>5</sup>Private Practice, Los Angeles, CA, <sup>6</sup>Genentech, Inc., South San Francisco, CA, <sup>7</sup>Quintiles, Inc., Morrisville, NC: **TROPICS 1: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Central Venous Catheters.** ASH 2009, Oral and Poster Abstracts
- RM Buowski,<sup>1</sup> WM Stadler,<sup>2</sup> RA Figlin,<sup>3</sup> JJ Knox,<sup>4</sup> **N Gabrail**,<sup>5</sup> DF McDermott,<sup>6</sup> L Cupit,<sup>7</sup> WH Miller, Jr.<sup>8</sup> J Hainesworth,<sup>9</sup> CW Ryan,<sup>10</sup> on behalf the ARCCS Investigators. <sup>1</sup> Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, Ohio, USA; <sup>2</sup>University of Chicago Medical Center, Chicago, IL, USA; <sup>3</sup> City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA; <sup>4</sup>Princess Margaret Hospital, Toronto, ON, Canada; <sup>5</sup>**Gabrail Cancer Center, Canton, Ohio, USA**; <sup>6</sup> Beth Israel Deaconess Medical Center, Boston, MA, USA; <sup>7</sup>Bayer Healthcare, West Haven, CT, USA; <sup>8</sup>Jewish General Hospital, McGill University, Montreal, PQ, Canada; <sup>9</sup> Sarah Cannon Research Institute, Nashville, TN, USA; <sup>10</sup>Oregon Health and Science University, Portland, OR, USA: **Safety and Efficacy of Sorafenib in Elderly Patients: A Subset Analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America.** ASCO 2008; Poster. June 2008
- David A. Rizzieri,<sup>1</sup> Eric Feldman,<sup>2</sup> John F. DiPersio,<sup>3</sup> **Nashat Gabrail**,<sup>4</sup> Wendy Stock,<sup>5</sup> Roger Strair,<sup>6</sup> Victor M. Rivera,<sup>7</sup> Maher Albitar,<sup>8</sup> Camille L. Bedrosian,<sup>7</sup> and Francis J. Giles<sup>9</sup> <sup>1</sup>Duke University Medical Center, Durham, North Carolina; <sup>2</sup>Weill Medical College of Cornell University, New York, New York; <sup>3</sup>Washington University Medical Center, St. Louis, Missouri; <sup>4</sup>Gabrail Cancer Center, Canton, Ohio; <sup>5</sup>University of Chicago Department of Medicine and Cancer Research Center, Chicago, Illinois; <sup>6</sup>Cancer Institute of New Jersey, New Brunswick, New Jersey; <sup>7</sup>ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts; <sup>8</sup>Quest Diagnostics, Nichols Institute, San Juan Capistrano, California; and <sup>9</sup>University of Texas Health Science Center at San Antonio, San Antonio, Texas: **A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients**



**with Relapsed or Refractory Hematologic Malignancies.** *Clin Cancer Research*: Volume 14: Number 9. May 2008

- V. L. Hansen, **N. Gabrail**, J. Levin, R. Bandekar, J. Herrstedt: **Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX); Subgroup analysis from a randomized, double-blind, placebo-controlled phase III trial.** Abstract- No. 359; 2008 Gastrointestinal Cancers Symposium; Category-Colon and Rectum. 2008
- E. Chan, P. O'Dwyer, **N. Gabrail**, L. Zuomei, A. Kalita, M. Trachy-Bourget, M. Tawashi, R. Ward, M. Drouin, H. Hurwitz; **Phase 1 trial of an oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination (combo) with gemcitabine (gem) in patients (pts) with refractory solid tumors.** Gastrointestinal Cancers Symposium; Category-Pancreas, Small Bowel, and Hepatobiliary Tract. Abstract- No.-181. 2008.
- Steven J Cohen, Cornelis J A Punt, Nicholas Iannotti, Bruce H Saidman, Kert D Sabbath, **Nashat Y Gabrail**, Joel Picus, Michael Morse, Edith Mitchell, M Craig Miller, Gerald V Doyle, Henk Tissing, Leon W M M Terstappen, Neal J Meropol: **Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.** *Journal of Clinical Oncology* ; Volume: 26: Issue: 19. Pages: 3213-3221. 2008
- **NY Gabrail**<sup>1</sup>, H Eliopoulos<sup>2</sup>, A Coates<sup>2</sup>, X. Zhou<sup>2</sup>, H Xiong<sup>2</sup>, A Hagey<sup>2</sup> **<sup>1</sup>Gabrail Cancer Center, Canton, Ohio; <sup>2</sup>Abbott, Abbott Park, Illinois: Phase ½ Study Evaluating the Safety and Efficacy of ABT-751 in Combination With Docetaxel Alone in Subjects With Advanced or Metastatic Non-small-cell lung Cancer (NSCLC); IASLC 2007; ASCO 2007.**
- Stephan Moll<sup>1</sup>, **Nashat Gabrail**<sup>2</sup>, Jim Buchanan<sup>3</sup>, Mohammad Hirmand<sup>3</sup>, Michael Levy<sup>3</sup>, Ralph Zitnik<sup>3</sup>, <sup>1</sup>University of North Carolina School of Medicine, Chapel Hill, NC; <sup>2</sup> **Gabrail Cancer Center, Canton, Ohio;** <sup>3</sup> Nuvelo, Inc., San Carlos, CA. **Safety and Efficacy of Afimeprase in Subjects with Occluded Central Access Devices: The SONOMA-2 Study.** ASH 2007. Abstract
- Steven M Grunberg MD<sup>1</sup>, **Nashat Y Gabrail MD**<sup>2</sup>, Gemma Clark<sup>3</sup>; <sup>1</sup>University of Vermont, Vermont Cancer Center, 89 Beaumont Avenue, Given E214-E, Burlington, VT 05405, USA; <sup>2</sup>**Gabrail Cancer Center, 4875 Higbee Ave NW, Canton, Ohio 44718, USA;** <sup>3</sup>Prostraken, Galabank Business Park, Galashiels, TD1 1QH, UK.: **Phase III trial of transdermal granisetron patch (Sancuso) compared with oral granisetron in the management of chemotherapy-induced nausea and vomiting.** MASCC 20<sup>th</sup> International Annual Symposium, St Gallen, Switzerland. No: 18. Abstract # 031207. Poster 27<sup>th</sup>-30<sup>th</sup> June 2007
- David A. Rizzieri, Duke University Medical Center, Durham, NC; Eric Feldman, Weill Medical College of Cornell University, New York, NY; John F DiPersio, Washington University Medical Center, St. Louis, MO; **Nashat Gabrail, Gabrail Cancer Center, Canton, OH;** Wendy Stock, University of Chicago Department of Medicine and Cancer Research Center, Chicago, IL; Roger Strair, Cancer Institute of New Jersey, New Brunswick, NJ; Victor M Rivera, ARIAD Pharmaceuticals, Cambridge, MA; Camille L Bedrosian, Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Francis J. Giles, University of Texas Health Science Center at San Antonio, San Antonio, TX. **A phase 2 trial of AP23573, a novel mTOR inhibitor, in patients with relapsed or refractory hematological malignancies.** Abstract, ASCO 2007.
- J. Knox, Princess Margaret Hospital, Toronto, ONT; R.A. Figlin, City of Hope Comprehensive Cancer Center, Los Angeles, CA; W.M. Stadler, University of Chicago Medical Center, Chicago, IL; D. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; **N. Gabrail, Gabrail Cancer Center, Canton, OH;** W. Miller, McGill University, Montreal, QC; J Hainsworth, Sara Cannon Research Institute, Nashville, TN; C.Ryan, Oregon Health and Science University, Portland, OR; L.Cupit and R Bukowski, Bayer Healthcare, West Haven, CT; Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH.: **The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy.** *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5011
- Spira, N. O. Iannotti, M. A. Savin, M. Neubauer, **N. Y. Gabrail**, R. Yanagihara, K. K. Datta, E. A. Zang, S.

Z. Fields, A. Das: **Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC).** *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7546

- Lowell B. Anthony, MD, LSUHCS, Stanley S Scott Cancer Center, New Orleans, LA; **Nashat Y Gabrail MD, Gabrail Cancer Center**, Canton, OH; Hassan Ghazal, MD, Kentucky Cancer Clinic, Hazard, KY; Donald V. Woytowicz, MD, Florida Cancer Specialists, Fort Myers, FL; Marshall S. Flam, MD, Hematology Oncology Group of Fresno, Fresno, CA; Anibal Drelichman, MD, Newland Medical Associates, 22301 Foster Winter Drive, Suite 200, Southfield MI; David M. Loesch, MD, Oncology Hematology Associates, Indianapolis, IN; Laszlo Boros, MD, Upstate NY Cancer Research and Education Foundation, Indianapolis, IN; Demi A. Niforos, MS, AAI Pharma, Natick, MA; Antoinette Mangione, MD, Pharm D, Luitpold Pharmaceuticals, Norristown, PA; Robert E. Bellet, MD, Luitpold Pharmaceuticals, Norristown, PA: **A Randomized Open-Label Multi Center Phase III Clinical Trial Comparing Iron Sucrose (Venofer) Intravenously to No Iron Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Stimulating Agent Therapy.** *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 9109.
- D. I. Quinn, J. Nemunaitis, J. Fuloria, C. D. Britten, **N. Y. Gabrail**, L. Yee, M. Acharya, K. C. Chan, P. Bishop, A. P. Dudov: **Open-label study to assess effect of omeprazole (O) on pharmacokinetics of bortezomib (B) in subjects with advanced solid tumors, NHL, or multiple myeloma.** *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 13000.
- Santoro, Istituto Clinico Humanitas, Rozzano, Italy; J. Voglova, Internal Clinic Dept. of Clinical Haematology, Hradec Kralove, Czech Republic; **N. Gabrail, Gabrail Cancer Center, Canton, OH**; T. Ciuleanu, Oncology Insitute, Cluj-Napoca, Romania; M. Liberati, Universita degli studi di Perugia Policlinico Mont, Perugia, Italy; B. W. Hancock, Universita degli studi di Perugia Policlinico Mont, Perugia, Italy; S. Stromatt, Cell Therapeutics, Inc., Seattle, WA; D. Caballero, Hospital Clinico Servicio, de Hematologia, Salamanca, Spain: **Comparative Trial of Pixantrone + Rituximab vs Single Agent Rituximab in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL).** ASCO 2006.Poster. June 2006
- S. Rosenoff, **N. Gabrail**, R. Conklin, J. Hohnaker, W. Berg, J. Hedrick, G. Warsi, J. Benedetto, W. Zhu, L. Anthony; Oncology and Hematology Associates/US Oncology, Roanoke, VA; **Gabrail Cancer Center, Canton, OH**; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA: **A multicenter, randomized trial of long-acting octreotide (LAR) in the treatment of chemotherapy-induced diarrhea (CTID).**
- **Nashat Y. Gabrail**, Donald C. Doll, **Gabrail Cancer Center, Canton, OH, USA**; Hematology Oncology, University of Missouri Hospital and Clinics, Columbia, MO, USA: **Alfa Interferon Reverses Bone Marrow Fibrosis in Patients with Myeloproliferative Diseases.** ASH. Poster Session 644-III. Abstract #3424 *Blood*. Volume 102: Issue 11, November 16, 2003.
- **Nashat Y. Gabrail** 1, Chris Dvergsten 2 and Harry Ahdieh 3. **1 Private Practice, Canton, OH, USA. 2 INC Research, Charlottesville, VA, USA. 3 Endo Pharmaceuticals Inc., Chadds Ford, PA, USA: Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release inpatients with cancer pain: a randomized controlled study\***. *CURRENT MEDICAL RESEARCH AND OPINION®*. VOL. 20: NO. 6. 911–918. 2004
- **N. Y. Gabrail**, C. Dvergsten, T. Ma, A. Frailey, H. Ahdieh; **Private Practice, Canton, OH, Albania**; INC Research, Charlottesville, VA; Endo Pharmaceuticals Inc., Chadds Ford, PA: **Oxymorphone extended-release (ER) provides safe, effective, and rapid analgesia during opioid rotation. Results of a randomized, double-blind, crossover, comparative study with oxycodone controlled-release (CR).** MASCC/ISOO. 15th International Symposium Supportive Care in Cancer, June 18–21, 2003
- **N. Y. Gabrail**, C. Dvergsten, T. Ma, A. Frailey, H. Ahdieh; Private Practice, Canton, OH, Albania; INC Research, Charlottesville, VA; Endo Pharmaceuticals Inc., Chadds Ford, PA: **Oxymorphone extended-**

**release (ER) provides safe, effective, and rapid analgesia during opioid rotation: Results of a randomized, double-blind, crossover, and comparative study with oxycodone controlled-release (CR).** ASCO 2003, June 2, 2003.

- **Nashat Y Gabrail: Possible Synergy between Arsenic Trioxide and Cyclosporin A in a patient with Myelodysplastic Syndrome.** Abstract. *Leukemia*. September 2002
- **Nashat Y. Gabrail: Meningeal Lymphoma.** *Oncology News*. Vol. 5: No. 5. May 1996.
- **Nashat Y. Gabrail: guest editor. Myeloproliferative diseases.** *Seminars in Oncology*. Vol. 22: No. 4. 1995.
- M.F. Doyle, Stanley Anderson, Carlos Cerrezvelle and **Nashat Y. Gabrail: Sezary Syndrome associated with phenytoin therapy.** *Acta Haematologica*. 92: 204-207. 1994
- **Nashat Y. Gabrail: Management of malignant chordoma.** *Oncology Times*, 1993.
- **Nashat Y. Gabrail.** Barbara Y. Zara: Letter to the Editor. **Pulmonary hemartoma syndrome.** *Chest*. Vol. 101: March 1992.
- **Nashat Y. Gabrail:** Letter to the Editor. *Chest* 101:31. March 1992.
- **Nashat Y. Gabrail.** Bruce Harrison, Joung Sunwoo: **Chemo-irradiation induced aorta esophageal fistula.** *Journal of Surgical Oncology*. Vol. 48: p. 9213-9215. 1991.
- **Nashat Y. Gabrail.** Thomas Martin: **Co-existence of essential thrombocythemia and chronic lymphocytic leukemia.** *Acta Haematologica*. Vol. 85: p. 31-33. 1991.
- Michael Doyle. Stanley Anderson. **Nashat Gabrail: Dilantin induced mycosis fungoides.** *Acta Haematologica*. Vol. 85: p. 31-33. 1991
- **Nashat Y. Gabrail.** Barbara Y. Zara: **Pulmonary hemartoma syndrome.** *Chest*, Vol. 97: p. 962-965. April 1990
- **Nashat Y. Gabrail: Acute leukemia after adjuvant chemotherapy for breast cancer.** *Missouri Medicine*. Vol. 86: No. 10, p. 689-690. 1989
- **Nashat Y. Gabrail: High dose chemotherapy with bone marrow transplantation at St. Louis University Hospital.** *Oncology News*. Vol. 4: No. 1. 1989
- **Nashat Y. Gabrail.** John W. Yarbrow: Letter to the Editor. **Second cancer after radiation therapy for Hodgkins disease.** *New England Journal of Medicine*. Vol. 319: July 28, 1988
- **Nashat Y. Gabrail, R.R. Abbott: Comparative study of chemotherapy with or without radiation therapy in Stage II Breast Cancer.** Abstract. Proceedings of the 4<sup>th</sup> Adjuvant Chemotherapy Conference in Tucson, Arizona. 1987
- **Nashat Y. Gabrail.** R.R. Abbott: **Paraganglioma successfully treated with chemotherapy.** Abstract. Proceedings from the 4<sup>th</sup> Adjuvant Chemotherapy Conference, Tucson, Arizona, 1987.
- **Nashat Y. Gabrail: Severe febrile reaction to isoniazid.** *Chest*. Vol. 91: p. 620-621, April 1987